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Background: Following spinal cord injury (SCI) dramatic declines in sub-lesional bone mineral 
density (BMD) and deterioration of bone microarchitecture occur, and are associated with a high 
prevalence of fractures. Conventional risk factors for osteoporosis diagnosis in the non-SCI 
population put all individuals with SCI at a high risk of fracturing, however not all experience 
fractures. Vitamin D and parathyroid hormone (PTH) levels have been linked to skeletal health 
in the non-SCI population, and therefore may be a modifiable risk factor worth targeting to 
prevent bone loss post-SCI.  
Objectives: To evaluate: 1) the prevalence of suboptimal vitamin D (Serum 25(OH)D 
<75nmol/L) status and identify the relationships between 25(OH)D and bone quality; and 2) the 
prevalence of secondary hyperparathyroidism (Serum intact PTH ≥ 7.0 pmol/L) and identify the 
relationships between serum PTH and bone quality, in males and females with chronic SCI.  
Methods: Individuals were assessed via cross-sectional study design. Serum 25(OH)D was 
measured using a chemiluminescent immunoassay and serum intact PTH was measured using an 
electrochemiluminescent immunoassay. Bone quality parameters evaluated include: 1) DXA 
assessed distal femur and proximal tibia aBMD; and 2) pQCT assessed vBMD at the 4% tibia 
trabecular and 66% tibia cortical sites, and 66% tibia cortical thickness. Correlates of suboptimal 
vitamin D status were identified through univariate logistic regression analaysis. Pearson 
correlations were run to assess the relationships between the serum measures and the bone 
quality outcomes. Significance was p<0.05.  
Results: Thirty-eight percent of the included 45 adult males and females with chronic SCI had 
suboptimal serum 25(OH)D levels. Additionally, those with vitamin D assessed in the winter 
months (OR=6.3, p=0.022), not taking calcium supplements (OR=7.1, p=0.038), not taking 
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vitamin D supplements (OR=10.5, p=0.049), and of younger age (OR=0.92, p=0.038) were 
associated with suboptimal vitamin D levels. A weak, non-significant association was observed 
between PTH and serum 25(OH)D (r=-0.327, p=0.068) and there was a trend towards an inverse 
association between PTH and 66% tibia cortical thickness (r=-0.353, p=0.071).  
Conclusions: Many individuals with chronic SCI have suboptimal serum 25(OH)D levels, 
particularly in the winter months. Disruption of the vitamin D-PTH axis may contribute to the 
bone loss seen in the chronic SCI population, particularly in cortical bone. Optimal serum 
25(OH)D levels in the chronic SCI population may be higher than in the non-SCI population. 
This exploratory corrrelational study provides a framework for evaluation of relationships 
between 25(OH)D and bone quality in a larger cohort, adjusting for factors known to influence 
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In the years following SCI, individuals develop many secondary health complications.  To 
ensure quality of life for those living with SCI, it is important to manage complications such that 
maximum independence resumes. Following SCI extensive bone loss occurs, leaving individuals 
highly susceptible to fracturing. Fractures, for the SCI population, may require hospitalization 
resulting in further immobility and increased attendant care needs. Severe bone loss in those with 
SCI is particularly evident at sub-lesional levels and has been thought to be primarily a result of 
unloading; however other mechanisms have also been postulated. Current WHO guidelines for 
diagnosing osteoporosis in the non-SCI population are unsuitable for diagnosis in the SCI 
population; it does not allow for risk stratification, or for the ability to target treatments 
specifically. Potential fracture risk factors in persons with SCI include: injury completeness, 
alcohol consumption, increasing age and longer time post injury, low knee region aBMD and 
trabecular vBMD, low cortical vBMD, and low serum vitamin D and secondary 
hyperparathyroidism. Vitamin D, which primarily maintains serum calcium and phosphorus 
homeostasis, has been strongly linked to skeletal health in the non-SCI population, and therefore 
may be a modifiable risk factor worth targeting in those with chronic SCI. Based on the limited 
evidence to date, the prevalence of suboptimal vitamin D status and secondary 
hyperparathyroidism in the SCI population cannot be determined.  Furthermore, the relationship 
between vitamin D status and bone quality in individuals with SCI is not clear. Ultimately, 
identification of the relationship between vitamin D status and bone quality in individuals with 
SCI could aid in the development of a fracture risk assessment tool specific to persons with SCI, 









The number of Canadian’s living with a spinal cord injury (SCI) has been estimated to be greater 
than 36 000, with approximately 1100 new SCI’s occurring every year (1). The most commonly 
reported causes of SCI are trauma related, and include: motor vehicle accidents, sports injuries, 
and falls (1). Greater than 80% of injuries occur in people under the age of 35 years, and on 
average 80% of newly injured individuals are male (1). With the available expertise and 
advances in medical care, many who experience a traumatic SCI will live a normal lifespan, and, 
depending on the severity, will cost the Canadian Health Care system between 1.25 and 25 
million dollars each, over the course of their lifetime (1). It is necessary for continual progression 
in research on the management of the secondary complications which will burden those with an 
SCI for their entire lives. Body composition changes following SCI are suggested to increase risk 
of developing diseases including: coronary heart disease (2), diabetes mellitus (3), and 
osteoporosis (4; 5; 6); all of which affect quality of life. Changes in body composition that occur 
following SCI include: increased fat mass; muscle atrophy; and severe bone loss, particularly 
below the level of the lesion (7). Preventing complications associated with body composition 
changes secondary to SCI will help provide a better quality of life for those living with an SCI. 
The international standard for classification of a SCI includes the neurological level and 
severity of the injury as well as the American Spinal Cord Injury Association Impairment Scale 
(AIS) motor and sensory scores. Injuries are described based on the pattern and severity of motor 
and sensory fibre involvement. An AIS score of A indicates no preservation of motor or sensory 
fibres below the level of injury; where as a score of B indicates sensory preservation but no 
motor fibre preservation below the level of the injury. In other words both AIS scores of A and B 
are indicative of a motor complete injury. An AIS score of C or D means the injury is 
incomplete; that is, there is some motor preservation below the level of injury. Depending on the 
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amount of motor control preserved according to the motor scores for key muscle groups, 
individuals are classified differently; those with less motor control are given a score of C and 
those with more motor control are given a score of D. A score of E indicates normal motor and 
sensory function below the level of the injury. The neurological level of injury, whether they are 
paraplegic or tetraplegic and the AIS classification contribute to the type and severity of the 
secondary health complications after SCI. 
 
1.2.0. SPINAL CORD INJURY AND BONE HEALTH 
 
1.2.1. THE BURDEN OF FRACTURES POST-SCI 
Osteoporosis is a skeletal system disease characterized by low bone mass and compromised 
structural integrity of bone, resulting in an increased risk of fracture (8). The World Health 
Organization (WHO) defines osteoporosis as an areal bone mineral density (aBMD) 2.5 standard 
deviations or more below that of the young adult mean (9). Of 41 males with SCI assessed, Lazo 
and colleagues (10) showed that 61% met the WHO criteria for osteoporosis, and 19.5% were 
said to be osteopenic. More recently, in a cohort of 132 males with SCI, about 82% were 
diagnosed osteoporotic as defined by the WHO (11). Current guidelines for assessing 
osteoporosis and a ten-year fracture risk incorporate factors such as: femoral neck aBMD, 
glucocorticoid use, body mass index, alcohol consumption, smoking, secondary osteoporosis, as 
well as others (12). Many of the factors associated with declining bone health in the non-SCI 
population may not associate the same way in those with an SCI. For example, aBMD at the 
femoral neck in the SCI population is not measured because of technical artefacts such as 
contractures. Further, having an SCI is a cause of secondary osteoporosis, immediately 
increasing the ten-year fracture risk in those individuals. Therefore, the osteoporosis assessment 
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strategies used in the non-SCI population are not appropriate to predict fracture risk in the SCI 
population. 
Bone loss following SCI is of particular concern because of the high incidence of 
fragility, low trauma related, fractures in the lower limbs experienced in this population (13; 14). 
Fracture occurrence in individuals with SCI was identified as double that of the non-SCI 
population, with 19% of fractures classified as fragility in the SCI population, versus 1.4% 
classified as fragility in the non-SCI population (15). Furthermore, 25-34% of individuals with 
SCI have been reported to have sustained at least one fracture in the lower extremity during the 
time since their SCI (10; 13). Fractures in individuals with SCI often require hospitalization, 
resulting in further immobility, and greatly affect their quality of life. In the SCI population, the 
most frequent sites of fracture are the distal femur and proximal tibia (13; 16; 17), which are also 
the most commonly reported fracture sites requiring hospitalization (14). It is also noted that 
generally fractures above the knee joint line often requires open-reduction internal fixation 
versus fractures below the knee joint line which can often be treated with conventional casting 
(18). Common causes of fractures in the SCI population include falling from a wheelchair, 
transferring, and catching a foot or bumping into objects while manoeuvring a wheelchair (14; 
13); all low trauma related, and occur during activities of daily living. With so many individuals 
with SCI diagnosed with osteoporosis, it is necessary to identify SCI-specific risk factors that 
distinguish those who will experience fractures from those who will not, in order to provide the 






1.2.2. WHY FRACTURES OCCUR POST-SCI 
Sub-lesional declines in bone mass are well established complications following SCI. Acute 
aBMD losses in the lower limbs range from 20-32% (4; 6; 19). Similarly, a decrease in aBMD in 
the lower limbs from 10-25% is reported to occur within the first year of injury (5; 20). It has 
been previously suggested that aBMD reaches a steady state 1-2 years post injury (4), however 
few prospective studies have been done to verify this theory. One 3-year prospective study 
showed a 50% decrease in bone mineral content to occur in the lower limbs post SCI, suggesting 
that perhaps a steady state is not established at 2 years post injury, and bone loss continues to 
occur (21). Furthermore, the annual percent aBMD lost at the proximal tibia and distal femur in 
individuals with chronic SCI has been reported to be 1.5% and 1.1%, respectively (22).  
It is suggested that epiphysis trabecular bone mass loss occurs earlier, and to a greater 
extent, than diaphysis cortical bone mass loss, however cortical thinning has also been shown to 
be significant in the SCI population (23). Trabecular volumetric bone mineral density (vBMD) in 
the tibia has been shown to decrease 5% at 6 months post-injury and 15% at 12 months post-
injury, whereas cortical vBMD only decreased 7% at one year post-injury (24). More recently, 
Eser and colleagues (23) reported that in individuals with chronic SCI, trabecular vBMD 
decreased by 73% and 54% in the tibia and femur, respectively; and cortical thickness decreased 
by 33% and 35% in the tibia and femur, respectively. Additionally, Eser and colleagues (13) 
established a distal tibia trabecular vBMD fracture threshold of 72 mg/cm
3
, reporting about 33% 
of individuals with SCI to have lower limb vBMD values below this fracture threshold, and 
suggested  lower limb trabecular vBMD to be the most sensitive measure to identify individuals 




1.2.3. FACTORS CONTRIBUTING TO SUB-LESIONAL BONE LOSS POST-SCI  
Osteoporosis following SCI is considered to be caused by disuse and resultant unbalanced 
osteoblast and osteoclast activity. Normally, mechanical loading on bone tissue increases the 
amount of osteoblast activity, strengthening bones in regions of high stress, and reducing bone 
turnover and bone loss. Unloading, as occurs in SCI, is suggested to suppress osteoblast cells and 
induce osteoclast cell activation, leading to bone loss (25). Loss of muscle force post SCI has 
also been suggested to contribute to bone demineralization at rates as high as 4% per month (20). 
However, studies have reported no changes in BMD following the implementation of weight-
bearing activities in groups with disuse osteoporosis (26; 27); suggesting that unloading may not 
be the only factor influencing the pathogenesis of osteoporosis in the SCI population. In the non-
SCI older population, vitamin D was demonstrated to positively associate with cortical vBMD, 
and parathyroid hormone (PTH) was inversely associated with cortical vBMD (28); implicating 
vitamin D as a modifiable risk factor associated with bone loss. Bauman and colleagues (29) 
demonstrated mild secondary hyperparathyroidism to be present in a group of individuals with 
chronic SCI and low serum 25(OH)D levels. Acknowledging the role vitamin D plays in 
maintaining serum calcium and phosphorus homeostasis, along with the relationship existing 
between vitamin D and osteoporosis in non-SCI populations (30), both vitamin D and secondary 
hyperparathyroidism have been identified as potential contributors to the development of 
osteoporosis post-SCI (31). Although disuse is justified as a major contributor to bone loss 
following SCI, identification of fracture risk factors involved in the pathogenesis of osteoporosis 





1.2.4. OSTEOPOROSIS MANAGEMENT POST-SCI 
Several strategies have been evaluated for the management of osteoporosis in individuals with 
SCI, including: anti-resorptive drugs, lower limb loading, and lower limb electrical stimulation. 
Anti-resorptive drugs, also known as bisphosphonates, act to slow down osteoclastic 
reabsorption of bones, through induction of apoposis. When treated weekly for 12 months with 
70mg of alendronate, an oral bisphosphonate, declining aBMD acutely following SCI was 
attenuated (32). Pearson and colleagues (33) demonstrated lower limb aBMD preservation when 
individuals were treated with 800mg of the bisphosphonate etidronate, daily for 30 weeks; these 
results were however, only in a group of participants with an incomplete impairment who 
returned to walking within 3 months of their injury. The intervention of lower limb loading has 
also been tested for its affect on the declining BMD following SCI. Giangregorio and colleagues 
(27) showed no significant changes from baseline in peripheral BMD following 12 months of 
3x/week body-weight-supported treadmill training.  In contrast, individuals with SCI who 
performed daily standing for greater than 1 hour and at least 5x/week, demonstrated higher BMD 
in the lower extremities after 2 years (34). In addition, Chen and colleagues (35) evaluated the 
effect of functional electrical stimulation cycle ergometry on bone health after SCI and showed 
that after 6 months of 5x/week training, BMD at the distal femur and proximal tibia region 
increased significantly. Morse and colleagues (36) identified, in clinicians treating individuals 
with SCI, that only 40% of clinicians prescribe bisphosphonates, and about 50% prescribe 
vitamin D to their patients; and that lack of osteoporosis treatment following SCI is because 
there are no standardized protocols for diagnosing and evaluating the extent of bone loss. 
Although strategies have been evaluated with regards to preventing bone loss following SCI, 
there are no clinical guidelines for implementing them. 
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1.2.5. DIAGNOSING INCREASED RISK OF FRACTURES POST-SCI 
The WHO has criteria for diagnosing osteoporosis in the non-SCI population, using aBMD 
measured from dual energy x-ray absorptiometry (DXA) (9). Until recently, the clinical 
diagnosis of osteoporosis based only on aBMD from DXA scans has been the gold standard. In 
the non-SCI population, DXA scans are generally taken of the hip, the wrist and the spine, sites 
where there are available reference data for comparison. Diagnosing the degree of bone loss is 
based upon the number of standard deviations away from young normal aBMD values in the 
reference database. More recently there has been a shift toward using aBMD along with other 
important risk factors to clinically diagnose osteoporosis and determine a 10-year fracture risk. 
Risk factors pertaining to the non-SCI population include: glucocorticoid treatment and previous 
fragility fractures (37). The methods of diagnosing osteoporosis and fracture risk in the general 
population cannot be applied to individuals with SCI because all would be considered at an 
increased risk of fracturing; it does not allow for risk stratification or the ability to target those at 
highest risk (10). Although fracture risk factors for individuals with SCI have been identified, 
they have not been validated in prospective studies, and there is no standard protocol for 
including them in osteoporosis assessment; as such, these risk factors are not used by clinicians 
(36). Craven and colleagues (38) have suggested a paradigm for clinical assessment of 
osteoporosis following SCI, which includes risk factors specific to the SCI population. Fracture 
risk factors suggested for the SCI population include: injury completeness (14; 39), >5 alcoholic 
beverages consumed per day (14), increasing age and longer time post-injury (16; 39), knee 
region aBMD <0.78 g/cm
2
 (16), trabecular vBMD in tibia <72 g/cm
3
 and in the femur <114 
g/cm
3
 (13), and low cortical vBMD (40). Other potential risk factors suggested to target in an 
osteoporosis diagnosing regimen in individuals with SCI are assessment of serum vitamin D and 
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parathyroid hormone (PTH) levels, however these have not yet been well evaluated (41). 
Although bone loss following SCI is well established, risk factors may be able to distinguish 
between individuals with SCI who fracture from those who do not fracture. Furthermore, if 
modifiable risk factors could be identified, more informed treatment strategies could be 
implemented. Vitamin D deficiency and secondary hyperparathyroidism have been reported to 
be prevalent in SCI and should be considered as a potential modifiable risk factor worth targeting 
in the SCI population.  
 
1.3.0. VITAMIN D AND BONE HEALTH 
 
1.3.1. VITAMIN D METABOLISM 
Vitamin D is a vital hormone for the musculoskeletal system to maintain calcium homeostasis 
and has been implicated as a factor affecting bone health (42). Refer to Figure 1 (Appendix B) 
for an illustration of the following description of vitamin D metabolism, which was also 
explained by Holick (43). Vitamin D can be acquired by the human body via two mechanisms: 
through cutaneous synthesis with UVB exposure, and through ingestion as part of one’s diet or 
by supplementation. Synthesis in the skin is the primary method through which the body 
acquires necessary vitamin D; it is also attained through diet mainly from fatty fish sources such 
as salmon, as well as fortified milks and cereals. Whether vitamin D is synthesized in the skin or 
ingested, it is in an inactive state. Cutaneous synthesis of vitamin D involves UVB radiation 
interaction with 7-dehydrocholesterol in the skin to form pre-vitamin D3, which then through a 
heat-dependent process quickly forms vitamin D. Vitamin D from both ingestion and cutaneous 
synthesis travel in the blood via vitamin D binding proteins; first to the liver where it is then 
converted to 25-hydroxyvitamin D (25(OH)D), also referred to as calcidiol, by the enzyme 25-
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hydroxylase. Calcidiol is the major circulating form of vitamin D and is what clinician’s measure 
when assessing vitamin D status; it is also a biologically inactive form. The kidney cells, along 
with many other cells in the body, express 1α-hydroxylase and are responsible for converting 
25(OH)D into the active state 1, 25 dihydroxyvitamin D (1,25(OH)2D), also known as calcitriol. 
The amount of circulating 1,25(OH)2D is regulated in two ways; self regulation via negative 
feedback, and by serum levels of PTH, calcium, phosphorus and fibroblast growth factor-23 
levels. If serum levels of 1,25(OH)2D are sufficient, the kidneys turn excess into calcitroic acid 
which is then excreted into bile. The primary stimulus for hydroxylation of calcidiol in the 
kidneys to the active form of vitamin D is increased serum PTH levels, in response to low serum 
calcium and phosphorus concentrations. Accordingly, the most well recognized action of 
calcitriol is to increase serum calcium and phosphorus levels through regulation in the small 
intestine, bones, and the kidneys.  
 
1.3.2. ROLE OF VITAMIN D IN THE BODY 
Due to the primary responsibility vitamin D has in serum calcium and phosphorus homeostasis, 
it has been strongly linked to the maintenance of skeletal health. Vitamin D, once in its’ active 
form, acts similarly to that of other steroid hormones; the actions of 1,25(OH)2D are mediated by 
vitamin D receptors which initiate suppression or activation of gene transcription in target tissues 
(44). Refer to Figure 1 (Appendix B) for an illustration of the roles vitamin D has with respect to 
the bones, intestine, and kidney. The main actions of 1,25(OH)2D are regulation of calcium and 
phosphorus flux in the bones, intestine and kidneys. However, vitamin D receptors are also 
found in many other tissues, whereby having implications other than those related to calcium and 
phosphorus homeostasis (44; 44). With respect to bone tissue, active vitamin D can increase 
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calcium reabsorption as well as increase calcium deposition: 1) In states of low serum calcium 
concentrations, and decreased calcium availability from other sources, 1,25(OH)2D along with 
the resultant increased PTH is suggested to stimulate osteoclast maturation by up-regulating 
receptor activator for nuclear factor κ B ligand (RANKL), and thus initiate calcium reabsorption; 
or 2) In states of high serum calcium concentrations vitamin D has been identified as a down-
regulator of osteoprotegrin, an osteoclastogenesis inhibitory factor, as well as stimulating 
production of osteoblasts and thus is  implicated in bone formation (44). Another action of 
1,25(OH)2D in the body, the most “classical” action and ultimately also influencing skeletal 
health, is to increase intestinal absorption of calcium and phosphorus, in an effort to maintain 
adequate serum levels. The process of increasing intestinal absorption of calcium and 
phosphorus occurs when 1,25(OH)2D interacts with specific membrane receptors, increasing 
gene expression encoding for calcium transport proteins, such as calbindin (45). The third main 
role of 1,25(OH)2D in the body takes place in the kidneys, where it is implicated indirectly in 
serum calcium homeostasis via PTH stimulation of renal resorption of calcium, increasing serum 
concentrations of calcium (45). Recall that in states of low serum calcium, PTH release is 
increased. To summarize, the primary role of vitamin D is to maintain adequate serum calcium 
and phosphorus levels. If serum calcium levels decline, PTH release is enhanced and 
mobilization of calcium from the bones, kidneys, and intestine increase. If vitamin D is low and 
there is not enough calcium being absorbed from the intestines and kidneys, reabsorption from 
the bone stores increases, which can severely compromise skeletal health. Thus, it is clear why 
vitamin D deficiency has been implicated in the development of osteoporosis.  
Vitamin D receptors are found in many tissues throughout the body and thus vitamin D 
levels have been implicated in the development of diseases other than just osteoporosis, 
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including: multiple sclerosis (MS), cancer, and heart disease. Hypovitaminosis D has been 
identified as a risk factor for MS (46). Burton and colleagues (47) demonstrated a 41% reduction 
in the number of disease relapses following 1 year of vitamin D supplementation with 14000 IU 
per day. Additionally, in a cohort of 39 MS patients, treatment with 1000 IU per day of vitamin 
D for 6 months resulted in significantly increased anti-inflammatory cytokines (48). Vitamin D 
levels have also been implicated in cancer risk due to its effect in tissues such as the breast, colon 
and prostate through inhibiting angiogenesis and promoting apoptosis as well as controlling 
proliferation (49). Garland and colleagues (50) have suggested the incidence of breast cancer 
could be reduced by 30% if serum 25(OH)D levels are maintained above 100 nmol/L. The 
1,25(OH)2D that is produced in the kidneys is also suggested to down-regulate rennin and thus is 
involved in blood pressure maintenance (49). A randomized placebo controlled trial 
demonstrated that vitamin D therapy significantly decreases systolic and diastolic blood pressure 
following 6 months of therapy (51). Although the classical action of vitamin D in the health 
maintenance is through its effects on bone health, vitamin D has implications in many other 
tissues in the body, and as such vitamin D sufficiency may differ depending on the body system 
of interest.              
 
1.3.3. DEFINING OPTIMAL/SUBOPTIMAL VITAMIN D 
Currently, there is no universal definition of an optimal serum 25(OH)D level for bone health, 
therefore recommendations regarding sufficiency are controversial. As serum 25(OH)D levels 
decline, there is less mobilization of calcium from the intestine, bones, and kidneys into the 
blood, thus stimulating the parathyroid gland to increase PTH release. Subsequently, increased 
serum PTH stimulates greater conversion of 25(OH)D to the active form 1,25(OH)2D, which in 
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turn increases mobilization of calcium from the intestine, kidneys, and bones into the blood. In 
situations of low calcium availability from the intestine and kidneys calcium is predominately 
reabsorbed from bone tissue. Martinez and colleagues (30) demonstrated that lower bone mass 
was seen in individuals with elevated PTH levels in states of low serum 25(OH)D, suggesting 
that serum 25(OH)D levels should be maintained such that PTH release is maximally suppressed 
and consequently reabsorption of calcium from bones is minimized. The inverse relationship 
between serum 25(OH)D and PTH has been examined to determine the vitamin D level at which 
PTH begins to significantly rise; significant increases in PTH have been reported at 25(OH)D 
levels of 40 nmol/L (52), 78 nmol/L (53), and 110 nmol/L (54). A potential reason for such 
discrepancies in the level at which 25(OH)D affects serum PTH is the populations studied and 
their associated vitamin D status. Furthermore, it has been suggested that vitamin D sufficiency 
levels should consider the 25(OH)D levels at which maximum calcium absorption in the 
intestine is promoted, thereby maintaining serum calcium levels such that PTH release is 
suppressed (55). Heaney and colleagues (55) demonstrated that intestinal calcium absorption at 
an average 25(OH)D level of 86 nmol/L was 45-65% greater than that in individuals with an 
average 25(OH)D level of 50 nmol/L. Therefore, based on the relationship between PTH and 
25(OH)D as well as maximum intestinal calcium absorption, guidelines for the general 
population regarding sufficient vitamin D levels for maintaining skeletal health are generally 
considered to be serum 25(OH)D levels between 70 and 80 nmol/L (56). Accordingly, guidelines 
regarding the vitamin D intake needed to achieve serum levels in the 70 – 80 nmol/L range have 
been suggested to be 1000 IU per day (56; 57).  
Many factors, including: measurement technique, seasonal variation, skin pigmentation, 
dietary sources, and age, contribute to difficulties in defining “normal” or “optimal” vitamin D 
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levels. Differences in the assays used to measure serum 25(OH)D may limit the ability for a 
collaborative interpretation and a consensus of what adequate 25(OH)D levels are for health (58; 
59; 60). The lack of standardization and calibration procedures underline the problems that arise 
with the validity of serum 25(OH)D measurement techniques (59). Holick (61) proposed that 
radioimmunoassay and vitamin D binding protein assays, which are typically used for 25(OH)D 
evaluation, can overestimate levels by approximately 10-20%. Another limitation to reports of 
vitamin D status is that some groups measured vitamin D based on food frequency 
questionnaires, which do not include estimates of vitamin D obtained from UVB exposure; the 
primary source of vitamin D in many individuals. Also, when evaluating food sources of vitamin 
D, it is important to know the bioavailability for each source in order to accurately estimate the 
amount of vitamin acquired. Through analysis of vitamin D content in a variety of fish, said to be 
the greatest dietary source of vitamin D besides fortified milk products, Chen and colleagues 
(62) identified that farmed salmon (the most widely consumed type of salmon in the US) 
contains only one quarter of the vitamin D provided from wild caught salmon. It is therefore 
important to be specific when recording vitamin D intake from dietary sources. Aside from 
differences in measurement techniques, there are seasonal differences in vitamin D synthesis, 
particularly in northern latitudes, which must be considered when attempting to establish the 
vitamin D status of a population. At 43˚N latitude, 25(OH)D levels were reported to be lowest 
between the months of November to April (52) due to the resultant zenith angle of the sun’s 
UVB rays (49). Another factor identified to significantly affect the amount of vitamin D that can 
be synthesized in the skin is pigmentation (62), which should be considered when assessing why 
certain populations may be more or less deficient. Conversion of 7-dehydrocholesterol to pre-
vitamin D3 in fair skin is shown to be 5-10 fold more efficient than in highly pigmented skin 
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(62), which contains more melanin and consequently absorbs more of the UVB rays (49). 
Finally, age has been identified as a factor limiting the amount of vitamin D that can be 
synthesized in the skin (49), and will affect what is considered “normal” depending on the 
population being studied. Due to the limitations in procedures for evaluating vitamin D and other 
non-modifiable factors such as skin pigment, latitude, and age, it is understandable why there is 
much controversy when attempting to establish what “normal” vitamin D values are in the 
general population. However, based on the general consensus that sufficient vitamin D status is 
at serum 25(OH)D levels between 70 and 80 nmol/L (56), it has been suggested that: 14% (53), 
greater than 28% (52) and greater than 61% (60), of healthy adults have insufficient vitamin D 
status. 
 
1.3.4. SUBOPTIMAL VITAMIN D AND OSTEOPOROSIS  
Vitamin D status has been identified as a factor of interest in the pathophysiology of osteoporosis 
due to its inverse relationship with PTH and the consequent effects on calcium reabsorption in 
bones. Serum 25(OH)D levels have been positively correlated with BMD at several skeletal 
sites, indicating that at lower levels of vitamin D, BMD tends to be lower (30; 63). Martinez and 
colleagues (30) demonstrated BMD at the femoral neck, trochanter, and Ward’s triangle to be 
significantly (p<0.05) correlated (r=0.29, r=0.27, r=0.30; respectively) with serum 25(OH)D 
levels in postmenopausal women over 60 years of age. In addition, Hannen and colleagues (63) 
found a significant positive correlation between BMD and 25(OH)D levels at five sites in a 
group of white men of varying ages. Lips and colleagues (64) evaluated vitamin D status in a 
large group of women with osteoporosis from 18 countries in varying degrees of latitude, and 
found that overall approximately 64% of women have serum 25(OH)D levels less than 75 
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nmol/L. Similarly, Kocjan and colleagues (65) found about 66% of patients attending an 
osteoporosis clinic to have serum 25(OH)D levels below 50nmol/L; and identified them as 
insufficient or deficient. It is important to note that calcium levels should also be reported when 
evaluating the relationship between vitamin D and bone health parameters to better identify 
whether changes in bone are associated with the vitamin D status or the calcium levels. Overall, 
low levels of vitamin D have been identified as a contributing factor to low BMD, and a greater 
proportion of individuals with osteoporosis appear to be vitamin D deficient compared to the 
non-osteoporotic population. Therefore, aside from the barriers involved in evaluating vitamin D 
status, the link between low serum 25(OH)D levels and poor bone health is recognized and 
should be considered when evaluating factors affecting osteoporosis development, treatment and 
fracture prevention. 
 
1.3.5. VITAMIN D SUPPLEMENTATION AND FRACTURE RISK 
 Vitamin D supplementation has been evaluated with respect to fracture prevention in persons at 
risk of fracture in the non-SCI osteoporotic population. A significant reduction in risk of 
sustaining a hip or other non-vertebral fracture of 26% and 23%, respectively, was concluded 
from trials supplementing participants with vitamin D doses of 700 or 800 IU daily; whereas 
supplementation with 400 IU daily did not reduce fracture risk (66). It is not clear what dose of 
calcium should be administered along with vitamin D to optimize the reduction in fracture risk, 
or if doses higher than 800 IU daily of vitamin D are more beneficial in reducing the risk of 
fractures. Further, it is unclear if fracture risk reduction with vitamin D supplementation transfers 





1.4.0. SPINAL CORD INJURY AND SUBOPTIMAL VITAMIN D  
 
1.4.1. PREVALENCE OF SUBOPTIMAL VITAMIN D AND HYPERPARATHYROIDISM 
IN SCI 
 
As is suggested in the non-SCI population, vitamin D and calcium insufficiency/deficiency may 
be prevalent in the SCI population, and therefore a contributing factor to the declining bone 
health reported following injury. Serum 25(OH)D levels in individuals with SCI are reported to 
be significantly lower than controls (67), and no different from controls (29; 68). However, one-
third of individuals with chronic SCI were reported to have serum 25(OH)D levels less than the 
normal range suggested for the non-SCI population (29). More recently, the prevalence of 
vitamin D deficiency in the SCI population has been estimated as high as 93% (69). Further, a 
negative correlation has been identified between serum 25(OH)D and PTH, implying that 
vitamin D insufficiency and secondary hyperparathyroidism may be prevalent among individuals 
with SCI and result in accelerated bone reabsorption (29). Based on the limited evidence to date, 
the prevalence of vitamin D deficiency and/or secondary hyperparathyroidism in the SCI 
population cannot be established. It is not known whether the prevalence of vitamin D deficiency 
among men and women with varying injury levels differs. Furthermore, it is not known if the 
suggested sufficiency level for vitamin D to adequately suppress PTH is the same in the SCI 
population as it is in the non-SCI population.  
 
1.4.2. ACQUIRING VITAMIN D IN SCI 
Due to decreased mobility following SCI, many individuals in this population are  exposed less 
to the sun than non-SCI individuals, suggesting vitamin D synthesis may be low (29).  Also, 
individuals with SCI are often instructed to limit ingestion of calcium-containing foods acutely 
post injury to avoid hypercalciuria. As a result, vitamin D intake from food sources also declines 
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since many foods containing vitamin D contain calcium as well. Walters and colleagues (70) 
evaluated the nutrition of men and women with chronic SCI and identified, from a 24-hour 
recall, that median usual intakes of both vitamin D and calcium were significantly lower than the 
adequate intake levels for the general population of 200-600 IU/d and 1000-1200 mg/d, 
respectively. Opperman and colleagues (71) recently reported that of a cohort of 77 adults with 
SCI, 50% were consistent supplement users and that multivitamins, calcium, and vitamin D were 
the most frequently consumed; 25%, 20%, and 16% respectively. Accordingly, preliminary 
studies have been done evaluating the effect of vitamin D supplementation on vitamin D status 
among persons with SCI. Bauman and colleagues (72) demonstrated that with 800 IU of daily 
vitamin D supplementation for 12 months, average 25(OH)D levels were significantly increased 
to 56.16 nmol/L from 26.7 nmol/L at baseline. However, after 12 months of supplementation 9 
of the 40 participants were 25(OH)D deficient (<40 nmol/L), and only 8 participants reached 
levels greater than 75 nmol/L,  as well it was suggested that vitamin D doses greater than 800 IU 
per day are needed for greater than 12 months in order to replace vitamin D deficient individuals 
with SCI (72). Although preliminary work has been done to evaluate what doses of vitamin D 
are necessary to increase serum 25(OH)D to sufficient levels, sufficiency and deficiency levels in 
the SCI population have not been established. Identification of optimal levels of vitamin D 
required in the SCI population is required before recommended intake levels can be identified.  
 
1.4.3. SUBOPTIMAL VITAMIN D AND BONE HEALTH IN SCI 
A relationship may exist between vitamin D and bone health in the SCI population which could 
provide a potential therapeutic target for prevention of fracture in those with an SCI.  Bauman 
and colleagues (73) evaluated the effect of 800 IU of vitamin D, plus 1.3g of calcium, plus 4µg 
of a vitamin D2 analog, versus vitamin D and calcium supplementation plus a placebo, on BMD 
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in individuals with SCI. They found that in the placebo group, leg BMD was not significantly 
different at 24 months versus baseline: 1.030 g/cm
3
 versus 1.045 g/cm
3
, respectively (73). In the 
treatment group, percent leg BMD increased significantly in a subgroup of individuals who had 
never smoked, therefore it was suggested that the interaction of smoking and vitamin D status 
may be important links to bone loss following SCI (73).  
Research regarding the relationships between vitamin D status and BMD in persons with 
SCI is limited. Future research is necessary to define optimal vitamin D status, the implications 
of vitamin D levels on specific bone parameters, and potential interactions of vitamin D with 
other bone-modifying risk factors among persons with SCI. Based on work done to date, it is 
likely that vitamin D, PTH levels, and resultant alterations in calcium homeostasis contribute to 
bone loss following SCI. The ultimate goal would be to elucidate the relationship between 
vitamin D status and fracture risk in individuals with SCI enabling treatment implementation for 





2.0.0. RESEARCH QUESTIONS/HYPOTHESES 
2.1.0. RESEARCH QUESTIONS 
Based on the literature to date, the following research questions were proposed: 
2.1.1. PRIMARY RESEARCH QUESTIONS 
1. In a sample of males and females with complete or incomplete, chronic SCI, what 
proportion of participants have suboptimal vitamin D status and what proportion of 
participants have optimal vitamin D status defined as: 
 Suboptimal: Serum 25(OH)D concentration of <75 nmol/L; 
 Optimal: Serum 25(OH)D concentration of ≥75 nmol/L? 
2. What are correlates of suboptimal vitamin D status in those with chronic SCI? 
3. In a sample of males and females with complete or incomplete, chronic SCI, what is the 
relationship between serum 25(OH)D level and indices of bone quality at the tibia and 
femur; including distal femur and proximal tibia aBMD, 4% tibia trabecular vBMD, and 
66% tibia cortical vBMD and cortical thickness? 
2.1.2. SECONDARY RESEARCH QUESTIONS 
4. Among a sample of males and females with complete or incomplete, chronic SCI, what 
proportion of participants have secondary hyperparathyroidism, and what proportion of 
participants have PTH levels within the normal range defined as: 
 Secondary hyperparathyroidism: Serum PTH concentration of ≥ 7.0 pmol/L; 
 Normal PTH: Serum PTH concentration of 1.6 – 6.9 pmol/L? 
5. Among a sample of males and females with complete or incomplete, chronic SCI, what 
is the relationship between serum PTH and serum 25(OH)D, as well as between serum 
PTH and serum ionized calcium? 
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6. In a sample of males and females with complete or incomplete, chronic SCI, what is the 
relationship between serum PTH level and indices of bone quality at the tibia or femur; 
including distal femur and proximal tibia aBMD and 4% tibia trabecular vBMD, and 
66% tibia cortical vBMD and cortical thickness? 
2.2.0. HYPOTHESES 
It is predicted that the 4% tibia trabecular vBMD, from pQCT, will be positively associated with 
serum levels of 25(OH)D. It is also expected that knee aBMD, measured from the DXA scans, 
will be positively associated with serum 25(OH)D levels. Cortical thickness at the 66% tibia site, 
from pQCT analysis, is predicted to associate positively with serum 25(OH)D levels and 
negatively with serum PTH.  
Additionally, it is predicted that an inverse relationship will be seen between serum 
25(OH)D level and PTH level, and that a large proportion of the population will have suboptimal 







3.1.0. RESEARCH DESIGN, SETTING AND POPULATION 
3.1.1. STUDY DESIGN 
The primary and secondary research questions were addressed via a cross-sectional study design, 
evaluating the baseline data from a larger 2-year prospective study. The data collected to address 
the objectives of the entire 2-year study include: a) medical history, including injury etiology and 
impairment descriptors; b) DXA scans of the whole body, spine, hips, and knee region to 
determine aBMD; c) pQCT scans to obtain tibia vBMD, bone geometry, and trabecular structure 
data; and d) blood to measure serum levels of 25(OH)D, intact PTH, BSAP, CTX-I, and ionized 
calcium.  
 
3.1.2. STUDY SETTING 
Collaborations were established between the University of Waterloo, McMaster University, and 
the Toronto Rehabilitation Institute to run the current study. Participant’s medical history, DXA 
scans and blood draws were completed at Toronto Rehab Lyndhurst Centre, and the pQCT scans 
were performed at the Hamilton Health Sciences’ McMaster University Site. Data was 
transferred to the University of Waterloo for analysis. 
 
3.1.3. STUDY POPULATION 
A convenience sample of 45 adults with chronic SCI was assembled over an 18 month time 
period. To ensure that recruited participants were neurologically stable, and had established bone 
loss that typically occurs in the first two years following injury, only individuals who were two 
years post-injury were eligible to participate. In an attempt to establish a representative sample of 
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the SCI population, males and females as well as those with motor complete (AIS classification 




Participants were recruited primarily from: a) the Lyndhurst Long-term Follow-up Database of 
over 800 individuals with SCI who had previously consented to be contacted for research 
purposes; and b) Outpatient services at Lyndhurst Centre. Physicians and therapists from 
Outpatient Services in the Spinal Cord Rehab Program at Lyndhurst Centre identified and 
referred potential participants to the study. Potential participants identified by physicians were 
informed of their eligibility and were then asked if they were interested in learning more about 
the study. If the individual consented to be contacted, a referral form (Appendix A) was 
completed by the physician/therapist and sent to the research coordinator, who then contacted 
interested individuals by telephone. Other recruitment strategies employed include: 
advertisements on the Canadian Paraplegic Association website and newsletter, and a brief 
presentation at the Lyndhurst Fitness Centre.     
Potential participants, identified from the database or physician referral, were sent a letter 
of invitation (Appendix A) stating that a research assistant would contact them to determine their 
interest and eligibility for enrolment. For individuals who did not want to be contacted, a phone 
number was provided in the letter where they could leave a message opting out of the call. 
During the phone call to interested potential participants, the details of the study were explained 
(Appendix A). For interested individuals, eligibility for participation was evaluated on the phone 
via a telephone screening form (Appendix A). Eligible individuals were then scheduled for their 
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baseline testing visit, when written informed consent (Appendix A) was obtained, and further 
screening was completed (Appendix A).  
The following were the study inclusion and exclusion criteria: 
Inclusion Criteria Exclusion Criteria 
 Able to understand instructions in 
English  
 A spinal cord impairment (C2-T12 
AIS A-D) of sudden onset (<24 hours) 
associated with a stable upper motor 
neuron, neurologic deficit of trauma or 
trauma-like etiology having occurred 
at least 24 months prior to study 
inclusion 
 Ability to give informed consent 
 Age > 18 years 
 Current or prior known conditions other than paralysis 
known to influence bone metabolism including: oral 
glucocorticoid use for ≥3 months, malignancy, known 
liver or malabsorption condition 
 Weight > 270 lbs (limit for bone density machine) 
 Contraindications to pQCT testing (e.g. bilateral metal 
implants, severe spasticity and allergy to Ativan) 




3.2.2. MEDICAL HISTORY AND DEMOGRAPHICS 
At the baseline visit, several questionnaires/forms were completed in interview format. Data 
regarding past and current medical health, medication use, lifestyle and demographic data, 
fracture history, and information related to the SCI were collected (Appendix A). Medical 
history, injury information, and impairment descriptors were abstracted from the patient’s 
medical record to confirm and supplement information provided by the participant. A physiatrist 
(C. Craven) determined the participants’ AIS classification by verifying the injury level and 
completeness for individuals whose impairment descriptors were not available in their medical 
record. Height, weight, waist circumference, calcium intake, and supplement use were also 
collected. Dietary calcium intake was assessed via a food frequency questionnaire (74), and 
severity of spasticity was evaluated using the Penn Spasm Frequency and Severity Scale (75) to 




3.2.3. BLOOD COLLECTION FOR SERUM ANALYSIS 
At the baseline visit, blood collection was performed by a trained phlebotomist. For proper 
analysis of the serum measures, participants were required to fast for at least 12 hours prior to 
blood collection.  For those participants unable to fast, a standard breakfast of toast and apple or 
orange juice was allowed, in which case blood was drawn 4 hours following food consumption. 
Blood samples were drawn using a closed, sterile Vacutainer® system. The skin superficial to 
the vein was cleaned with an alcohol wipe and a tourniquet applied 5-10 cm above the intended 
site of venous puncture. The needle was inserted through the skin and into the vein at an angle of 
15-30 degrees. Upon completion of the blood collection, two 10mL Vacutainers® per 
participant, the tourniquet was removed, the needle withdrawn from the vein quickly, and sterile 
cotton was pressed on the site of venous puncture. Pressure was applied for up to ten minutes to 
stop the bleeding and reduce the risk of bruising. Once the bleeding had subsided or stopped (2-3 
min), a sterile bandage was applied over the site.  Immediately following blood collection, the 
blood from one 10 mL Vacutainer® serum separater tube was left to clot for 10-30 minutes, and 
then was centrifuged at 4°C, 2800 rpm, for 15 minutes. The serum layer was carefully removed 
and distributed into 2 labelled 1.5mL microcentrifuge tubes that were stored in a -70
o
C freezer 
for back up analysis. The second 10 mL tube was placed on ice and sent to the Research 
Laboratory at Mt. Sinai Hospital for analysis. All analyses were completed on the day of the 
blood draw. All samples were stored in tubes labelled with an ID number; no identifying 
information was written on any storage tubes.   
Analysis for serum levels of 25(OH)D; PTH; BSAP, a marker of bone formation; C-
telopeptide of type I collagen (CTX-I), a marker of bone resorption; and ionized calcium were 
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completed for each participant. To address the primary and secondary research questions serum 
25(OH)D, PTH and ionized calcium were evaluated.  
 Serum 25(OH)D was determined with a chemiluminescent immunoassay (CLIA) using 
the DiaSorin LIAISON® instrument as the platform (DiaSorin, Stillwater, MN); which detects 
both 25(OH)D2 and 25(OH)D3 to estimate the total 25(OH)D circulating in the body. The 
DiaSorin LIAISON® CLIA uses an antibody against 25(OH)D to isolate serum 25(OH)D from 
other materials and metabolites. Once the 25(OH)D is isolated, reagents are added to the sample 
to initiate a flash chemiluminescent signal which can then be measured and related to the 
25(OH)D concentration (76). Serum 25(OH)D is particularly difficult to measure due to its 
lipophilic nature, and because the assay must be able to detect both 25(OH)D2 and 25(OH)D3 
equally (77). A common 25(OH)D measurement method used in other research evaluating the 
relationship between 25(OH)D and bone health is the DiaSorin 25(OH)D radioimmunoassay 
(RIA) kit (78). The DiaSorin LIAISON® CLIA has however demonstrated acceptable within 
assay precision (2.8 – 13%) and interassay precision (7.3 – 17.5%) when evaluated against the 
DiaSorin RIA as a reference method (79; 80). Additionally, the LIAISON® CLIA exhibits 100% 
cross-reactivity for both 25(OH)D2 and 25(OH)D3 (80).  
 PTH was determined with an electrochemiluminescent immunoassay (ECLIA) using the 
Roche Elecsys 1010/2010 and modular analytics E170 immonoassay analyzers (Roche 
Diagnostics, Mannheim, Germany). The Roche Elecsys 1010/2010 ECLIA uses a similar process 
to a CLIA to measure the serum intact PTH concentration. The ELCIA method differs from 
CLIA analysis in that a voltage is applied to initiate the chemiluminescent reaction (81). The 
Elecsys platform for measurement of intact PTH is demonstrated to be a reliable tool for 
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measuring intact PTH with within-run precision of 3.1 – 6.6% and between-day precision of 3.4 
– 15.6% found from a multicentre trial with 11 participating labs (82). 
Serum ionized calcium concentration was determined using potentiometers (ABL 735 
Analyzer). The ABL 735 Analyzer uses electrodes to relate the electrical potential of the ionized 
calcium in the serum sample to its concentration using the Nernst equation.  
Serum C-telopeptide of type I collagen was evaluated in post-hoc analyses. Serum CTX-I 
was measured with an ECLIA on the Roche Elecsys 1010/2010 and modular analytics E170 
immonoassay analyzers (Roche Diagnostics, Mannheim, Germany).    
 
3.2.4. PQCT SCANS 
PQCT scans were obtained at two sites on the tibia; one at the distal end for trabecular bone 
analysis and one at the tibia shaft for cortical bone analysis. The trabecular site was chosen for 
analysis based on previous work identifying trabecular vBMD as a good parameter for fracture 
prediction in the SCI population (13). Also, the cortical site was chosen based on previous work 
identifying an association between fractures and cortical bone parameters in a population with 
secondary hyperparathyroidism (83). In all participants, except those with severe spasticity or 
other contraindications, the right tibia was scanned. PQCT images were obtained with a Stratec 
XCT-2000 scanner (Stratec Medizintechnik, Germany), a translate-rotate small bore CT scanner 
that acquires a transaxial image from 145 projection scans. To obtain a measurement of leg 
length, the knee joint line and medial malleolus at the ankle joint were palpated and a measuring 
tape was used to measure the distance between them. The anatomic reference point, the tibia 
distal endplate, was identified on a 30mm coronal view of the ankle joint line on a scout scan. 
The scanning sites (at 4% and 66% of tibia length) were located measuring proximally from the 
29 
 
reference line identified in the scout scan. Single 2.5 mm slices were obtained at the ultradistal 
tibia (4% site) and the proximal one-third of the tibia (66% site). To obtain a resolution great 
enough to evaluate trabecular structure at the 4% site, a voxel size of 0.2 mm was used; whereas 
scans at the 66% site were done with a voxel size of 0.5 mm.  
To address the primary and secondary research questions, trabecular vBMD at the 4% 
site, and cortical vBMD and cortical thickness at the 66% site were assessed using the Stratec 
XCT commercial software package for the pQCT device. 
Trabecular vBMD at the 4% site was obtained using the CALCBD analysis mode in the 
commerical software package. The CALCBD analysis mode allows for the analysis of total bone 
and trabecular bone parameters separately. Within the CALCBD mode, contour mode 3 and peel 
mode 2 were applied, along with outer and inner thresholding of 130 and 400 mg/cm
3
, 
respectively, based on previous research demonstrating their accuracy (84). Contour mode 3 uses 
an iterative contour detection algorithm to find the outer bone edge. As stated, a threshold of 130 
mg/cm
3
 was applied to the outer edge detection method. Within the region of interest, one voxel 
is found with bone density equal to or above 130 mg/cm
3
 on the outer edge of the bone. The 
software then searches the adjacent voxels for a density equal to or greater than the previous. 
This process is continued until the whole outer edge of the bone is detected, which separates the 
bone from all muscle, fat and skin around it. Next, peel mode analysis was applied to separate 
the trabecular bone from the total bone. The trabecular bone is determined as all the voxels 
remaining which are below the applied threshold in the peel mode. Using the 400 mg/cm
3
 
threshold, the trabecular bone was distinguished from the subcortical bone. From the remaining 
area, trabecular vBMD was determined and extracted from the analysis.  
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The 66% site was analyzed using the CORTBD analysis mode, which provides cortical 
bone parameters. CORTBD mode 1 was used with a threshold of 711 mg/cm
3
, based on 
manufacturer’s suggestion. CORTBD mode 1 removes any voxels on the inner or outer edge 
with a density below the defined threshold. The remaining area is the cortical bone separated 
from the subcortical and trabecular bone, as well as any muscle, fat, and skin. From the 
CORTBD analysis, cortical vBMD and cortical thickness parameters were extracted for 
evaluation.  
 
3.2.5. DXA SCANS 
Areal BMD (g/cm
2
), or aBMD, of the right distal femur and right proximal tibia were gathered 
from densitometric scans using the Hologic 4500 dual-energy x-ray absorptiometry device 
(Hologic Inc., MA, USA). The knee region is a common site of fracture in the SCI population 
and was therefore chosen as the primary region of interest. Further, the DXA tool is the current 
standard for clinical assessment of BMD. Distal femur and proximal tibia scans were obtained 
and analyzed using a lower extremity positioning device and protocol, which has been previously 
determined as reliable and accurate (85). The method of distal femur and proximal tibia analysis 
uses a modified version of the manufacturer developed lumbar spine analysis protocol. The 
lower extremity positioning device was used to minimize movement during the scan and to 
ensure reliable overlap of the patella and proximal fibula with respect to the tibia. All DXA scans 
were performed and analyzed by trained technologists in the Bone Density Lab at Lyndhurst 
Centre. The DXA device at Lyndhurst is equipped with a lifting assist for safe transferring of 
participants to and from the scanning table.  
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To address the primary and secondary research questions, aBMD of the distal femur and 
proximal tibia were retrieved.   
 
3.2.6. OVERVIEW OF ASSESSMENT PROCESS 
After obtaining written informed consent at the baseline visit, each individual: 1) completed the 
questionnaires pertaining to demographic and medical history information at Lyndhurst Centre 
(~30 minutes); 2) participated in blood collection at Lyndhurst Centre (~10 Minutes); 3) 
participated in DXA scans at Lyndhurst Centre (~1 hour); 4) attended McMaster University 
Medical Centre to participate in pQCT scans of the tibia (~45 minutes); and 5) participated in a 
telephone interview when the physical activity and food frequency questionnaires were 
completed (~30-45 minutes). 
 
3.2.7. STATISTICAL ANALYSES 
To address the primary research questions and identify the proportion of the population with 
suboptimal vitamin D status, serum 25(OH)D levels were summarized using descriptive 
statistics: mean (standard deviation), as well as number (percent) for each suboptimal (<75 
nmol/L) and optimal categories (≥75 nmol/L). Additionally, univariate logistic regression 
analysis was performed to identify characteristics associated with suboptimal vitamin D status. 
The following characteristics were chosen to be assessed based on previous work in the non-SCI 
population: time of year, (52), age (49), gender (86), hyperparathyroidism (87), and obesity (88). 
Obesity was defined based on age and gender specific percent body fat ranges proposed by 
Gallagher and colleagues (89). Further, injury level (67), injury completeness (70), duration of 
injury (90), and supplement use (70) were chosen for assessment based on previous work 
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evaluating vitamin D in the SCI population. Additional characteristics assessed include: 
bisphosphonate use (91), and smoking status (12), due to their implications with bone health in 
the SCI and non-SCI populations. Odds ratios, 95% confidence intervals (CI), and p values were 
reported.  
To characterize and describe the bone health of the population, Z scores at the hip region, 
commonly used to assess fracture risk in the pre-menopausal non-SCI population, were 
calculated. The Z score compares the bone mass to an age and gender matched distribution. A 
BMD with a corresponding Z score ranging from -1 to -2.5 was considered to have low bone 
mass and increased risk of fracturing, whereas a Z score of -2.5 or below was considered 
osteoporotic and at the highest risk of fracturing (9). Additionally, bone quality was assessed 
based on SCI-specific aBMD fracture thresholds in the knee region and vBMD fracture 
thresholds for the 4% trabecular site in the tibia (13; 16). Previous work reports that the fracture 
threshold, the value at which fractures begin to occur, and the fracture breakpoint, the value at 
which fractures are likely to occur, at the knee region using DXA assessed aBMD in individuals 
with SCI is 0.78 g/cm
2
 and 0.49 g/cm
2
, respectively (16).  Additionally, fractures have been 
demonstrated to occur at the distal tibia in individuals with SCI whose vBMD values were below 
72 mg/cm
3
 measured through pQCT (13). Although trabecular vBMD is suggested to be a more 
sensitive parameter for bone quality assessment compared to cortical thickness and cortical 
vBMD parameters (13), lower extremity cortical vBMD has been shown to change in the first 5 
years following an SCI (92), and thus was included in the current analyses assessing 
relationships between bone parameters and serum 25(OH)D, post-SCI. To evaluate the 
relationship between serum 25(OH)D levels and all bone parameters, Pearson correlation and 
simple regression analyses were completed.  
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To address the secondary research questions and identify the proportion of the population 
with secondary hyperparathyroidism, serum PTH levels were summarized using descriptive 
statistics: mean (standard deviation), as well as number (percent) within each category; those 
within the normal serum PTH range (1.6 – 6.9 pmol/L) and those above the upper limit of the 
normal range (≥7 pmol/L). Additionally, Pearson correlation and simple linear regression 
analyses were completed to evaluate the relationship between serum PTH and serum 25(OH)D, 
and between serum PTH and ionized calcium. To evaluate the relationship between serum PTH 
levels and all bone parameters, Pearson correlation and simple regression analyses were 
completed. Post-hoc analyses included Pearson correlations between serum PTH and CTX-I and 
between serum 25(OH)D and CTX-I. Serum C-Telopeptide is a biomarker of bone resorption. 
Correlation coefficients (r) and p values were reported for all correlation analyses.  A p 
value of 0.05 was considered significant. For correlation coefficients from 0.00 – 0.09, variables 
were considered not associated, 0.10 – 0.29 weakly associated, 0.30 – 0.49 moderately 
associated, and >0.50 strongly associated. Additionally, linear regression equations and the 
proportion of variance explained by the independent variables analyzed (R
2
) were reported for all 
simple regression analyses. All analyses were done with SAS version 9.1 (Cary, North Carolina).  
 
3.3.0. ETHICAL CONSIDERATIONS 
3.3.1. POTENTIAL RISKS TO PARTICIPANTS 
During both the DXA and pQCT scans, participants were exposed to small amounts of radiation. 
The total amount of radiation exposure from both scans is approximately 30-35µSv; less than 
that received during an axial CT scan (30-60µSv) or annually from background radiation 
(2500µSv). Participants with severe spasticity were assessed by a physician (C. Craven), and 
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prescribed 0.5-l mg sublingual Ativan (anti-spasticity medication) prior to pQCT scanning if 
indicated. Administration of Ativan was a precaution taken to reduce the potential for injury if a 
spasm were to occur when the leg was positioned in the scanning device. Side effects associated 
with Ativan include: dizziness, weakness, drowsiness, dry mouth, and potentiating other anti-
spasticity medications. Participants were provided the opportunity to decline using Ativan.     
 
3.3.2. ANONYMITY  
The current research project was conducted following the Tri-Council Policy Statement 
regarding research with human participants (93). The current project holds Research Ethics 
Board approval at each site: The University of Waterloo, Toronto Rehabilitation Institute, and 
McMaster University. Each participant was assigned a unique identification (ID) number which 
was used on all forms and files in an electronic database. The key file linking participant 
information to the ID numbers was stored on a password protected computer. A CD backup copy 
and hard copy of the key file and data files were stored in separate, locked filing cabinets. 
Empower, at the University of Western Ontario, created a database for electronic 
compilation of all research data obtained. Indirect identifiers collected and entered in the 
database were date of birth and date of spinal cord injury. At the end of the 2-year prospective 
study all information from this database will be downloaded by Dr. Craven and Dr. Giangregorio 
and kept on file at Lyndhurst Centre indefinitely.   
 
3.3.3. FEEDBACK TO PARTICIPANTS 
After the completion of the larger 2-year study, a letter (Appendix A) will be sent to participants 





4.1.0. RECRUITMENT AND SAMPLE SIZE 
Two-hundred and fifty-two individuals were approached to participate in a larger two-year 
prospective study looking at bone quality over time in individuals with chronic SCI. Of those 
approached, 139 were unreachable by phone, 52 declined participation, and the remaining 61 
were pre-screened for eligibility. Four potential participants did not meet inclusion criteria, nine 
declined further participation, and 48 were determined eligible and agreed to participation. At the 
time of data analysis, 39 were included, and nine were pending assessment completion. Six 
additional subjects were included in the analysis from another ongoing study which provided 
some of the same outcome assessments, therefore increasing the total sample size to 45 
individuals with chronic spinal cord injury.  
Five participants were unable to have either their distal femur or proximal tibia scanned 
by DXA due to having hardware in the knee region; hardware interferes with the x-ray 
attenuation and would facilitate an invalid BMD measurement if scanned. Additionally, one 
individual was not scanned because their weight exceeded the tolerance of the scanning bed, and 
one individual only provided a proximal tibia scan due to a broken distal femur.  Therefore, 38 
distal femur and 43 proximal tibia BMD measurements via DXA were included in the final 
analyses. Three serum samples were not obtained due to difficulty drawing blood by the 
phlebotomist, and one individual declined the blood draw.  In three additional cases, 
measurement tests were missed by the analysis lab (2 PTH, 1 25(OH)D), and the six participants 
data added from the other study did not provide PTH or ionized calcium measurements. 
Therefore, 39 25(OH)D, 33 PTH and 34 ionized calcium measurements were included in the 
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final analyses. Some individuals were unable to travel to Hamilton to complete the pQCT scan, 
or were not scanned within the three month window of time for the baseline assessment to be 
completed. One participant experienced spasms, preventing safe scanning at the 66% site, and 
two additional 66% scans were not obtained due to positioning difficulties. Therefore, 38 scans 
at the 4% site and 37 scans at the 66% site of the tibia were included in the final analyses. Figure 
2 (Appendix B) summarizes participant recruitment and the sample sizes attained for the various 
outcomes. 
 
4.2.0. PARTICIPANT CHARACTERISTICS 
All 45 participants acquired their SCI from a traumatic event, and were at least two years post 
injury. The cohort consisted of thirty-four male and eleven female participants, with a mean age 
of 51±11.9 years and a mean percent body fat of 31.0 ± 7.5
 
(Table 1). The time post injury of 
participants ranged from 2 – 41 years with a mean of 14.7±10.3 years. Twenty-six participants 
were paraplegic; of which twenty-one had motor complete injuries, and five had motor 
incomplete injuries. Twenty-two participants were tetraplegic; of which nine had motor complete 


















Table 1. Participant Characteristics 
*Note. Values are mean (SD)  
 
 At the time of assessment, 89% of participants were taking vitamin D supplements, and 
82% of participants were taking calcium supplements. The range of vitamin D supplement doses 
consumed was from 200 IU to 5000 IU per day, with one individual self reporting a vitamin D 
intake of 50 000 IU per day for the last 18 months. Of those taking vitamin D supplements, 57% 
reported consuming greater than 1000 IU per day. Less than 50% of participants were currently 
taking a multivitamin. Average daily dietary calcium intake, as reported from the participants’ 
recall of their usual dietary habits in a month, was 991.4±1850 mg/day. At the time of 
assessment, twenty-six participants were currently on bisphosphonate therapy for improving 
their bone health, zero reported consuming an average of greater than five alcoholic beverages 
per day, eleven were current smokers, and twenty-five reported a history of smoking. Of the 
thirty-nine serum 25(OH)D measurements collected, twenty-seven were assessed in the summer 
months (May through October), and twelve were assessed in the winter months (November 
through April). The participants’ assessments were completed between April 2009 and August 
2010. Table 2 summarizes additional population descriptors for the cohort. 
 Male Female Total 
Total n 34 11 45 
Age (years)  51 (±11.5) 53 (±13.4) 51 (±11.9) 
Height (cm)  177.7 (±7.7) 166.7 (±5.1) 175.0 (±8.6) 
Weight (kg)  87.9 (±24.3) 73.9 (±19.1) 84.4 (±23.7) 
Body Fat (%)  29.4 (±6.7) 37.0 (±8.1) 31.0 (±7.5) 
    
Injury Characteristics    
 Motor Complete Paraplegia (n) 16 5 21 
 Motor Incomplete Paraplegia (n) 3 2 5 
 Motor Complete Tetraplegia (n) 8 1 9 
 Motor Incomplete Tetraplegia (n) 10 3 13 




    Table 2. Population descriptors and potential confounders for cohort (n=45) 
   















     *Indicates n=39 due to incomplete data sets 
 
4.3.0. BONE QUALITY 
The distal femur and proximal tibia DXA scans and the tibia pQCT outcomes reveal the bone 
loss in the current cohort of individuals living with an SCI.   Mean (SD) of the distal femur 
aBMD and proximal tibia aBMD were 0.634 (± 0.218) g/cm
2
 and 0.497 (± 0.168) g/cm
2
, 
respectively (Table 3). Based on Z-scores at the total hip, 37% have low bone mass (Z = -1- -
2.5), putting them at an increased risk of fracturing. Further, 29% have osteoporosis (Z ≤ -2.5), 
putting them at the highest risk of fracturing. Mean (SD) of the 4% tibia trabecular vBMD, 66% 
tibia cortical thickness, and 66% cortical vBMD were 140.12 (±54.9) mg/cm
3
, 3.26 (±1.01) mm, 
and 1081.1 (±58.3) mg/cm
3
, respectively.   
 
Table 3. Summary of bone quality outcomes for cohort 
 n (%) 
On Vitamin D  40 (89%) 
On Calcium  37 (82%) 
On Multivitamin  22 (49%) 
Average Dietary Calcium Intake/Day (mg/day)(Mean ± SD)* 991.4 (±1850.4) 
Using Bisphosphonates  26 (58%) 
Current Smoker  11 (24%) 
History of Smoking* 25 (64%) 
Consume >5 alcoholic drinks/day* 0 (0%) 
  
Summer Assessment (May-Oct)* 27 (69%) 
Winter Assessment (Nov-April)* 12 (31%) 
Outcome Mean (SD) Minimum Maximum 95% CI 
DXA     
 Distal Femur aBMD (g/cm2) (n=38) 0.634 (±0.218) 0.311 1.007 0.562 – 0.706 
 Proximal Tibia aBMD(g/cm2)  (n=43) 0.497 (±0.168) 0.157 0.880 0.445 – 0.549 
pQCT     
 4% Tibia Trabecular vBMD (mg/cm3) (n=38)  140.12 (±54.9) 44.3 245.2 122.1 – 158.2 
 66% Tibia Cortical vBMD (mg/cm3) (n=37 ) 1081.1 (±58.3) 889.1 1180.8 1061.6 – 1100.6 
 66% Tibia Cortical Thickness (mm) (n=37)  3.26 (±1.01) 0.78 5.66 2.92 – 3.60 
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Based on SCI population specific fracture thresholds developed mainly from males with 
motor complete injuries, our cohort of participants are representative of those at high risk of 
fracturing. In the current study 67% and 30% of participants had distal femur aBMD values 
below the fracture threshold and fracture breakpoint, respectively. Of the 30% below the fracture 
breakpoint, 30% had suboptimal vitamin D status. Also, 92% and 54% of participants had 
proximal tibia aBMD values below the fracture threshold and fracture breakpoint, respectively. 
Of the 54% of participants with proximal tibia aBMD values below the breakpoint, 25% 
demonstrated values below optimal vitamin D status. The current study demonstrated 6% of the 
sample to have pQCT measured distal tibia vBMD values below the fracture threshold suggested 
by Eser and colleagues (13). Of those below the threshold, only 1 individual had suboptimal 
vitamin D status. Based on the fracture threshold and breakpoint from DXA assessed knee 
aBMD in the literature, a large proportion of our sample are at an increased risk of fracture in 
that location. Based on the fracture threshold from pQCT assessed distal tibia vBMD in the 
literature, a small proportion of our sample are at risk of fracturing in that location. The studied 
cohort of individuals with chronic SCI has quite poor bone health and is at high risk of 
fracturing. Evaluating the relationships between bone health and 25(OHD in the current group of 
individuals at a high risk of fracturing provides information specific for the population that may 
benefit most from optimal vitamin D levels. 
 
4.4.0. VITAMIN D STATUS 
Thirty-eight percent (95% CI, 22.7 – 53.3) and 62% (95% CI, 46.7 – 77.3) of the population had 
serum 25(OH)D levels in the suboptimal (<75 nmol/L) and optimal (≥75 nmol/L) ranges, 
respectively. The mean (SD) serum 25(OH)D levels in nmol/L, and the 95% confidence intervals 
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within the suboptimal category was 55.9 (± 11.8) nmol/L (95% CI, 49.4 – 62.4) and ranged from 
33.0 – 74.0 nmol/L, whereas that in the optimal category was 109.3 (± 33.7) nmol/L (95% CI, 
95.1 – 123.5) and ranged from 76.0 – 226.0 nmol/L. The median serum 25(OH)D level in the 
suboptimal and optimal groups were 57 nmol/L and 102 nmol/L, respectively. Figure 3 
illustrates the scatter of serum 25(OH)D levels for all participants. 
 
Figure 3. Serum 25(OH)D level (nmol/L) for all participants (n=40)  illustrating those in the suboptimal and 
optimal ranges.   
 
Univariate logistic regression analysis was performed to identify which population 
characteristics were associated with vitamin D deficiency. Table 4 identifies the variables 
included in the analysis, the associated odds ratio (OR), and the 95% CI and p value. Those with 
vitamin D assessments performed in the winter months (OR=6.3, C.I.=1.3-30.5, p=0.022), and 
those not taking vitamin D (OR=10.5, C.I.=1.0-108.7, p=0.049) or calcium (OR=7.1, C.I.=1.1-
45.5, p=0.038) supplements were at an increased odds of being vitamin D deficient. 
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individual was increased the odds of being vitamin D deficient (OR=0.92, C.I.=0.8-0.9, 
p=0.038).  
     Table 4. Characteristics associated with vitamin D deficiency from univariate logistic regression analysis (n=34) 
     *Significant (p<0.05) 
 
4.5.0. RELATIONSHIP BETWEEN 25(OH)D AND BONE QUALITY OUTCOMES 
Serum 25(OH)D level was not significantly correlated with any bone quality outcomes. There 
was a weak negative, non-significant correlation between distal femur aBMD and serum 
25(OH)D level (r=-0.160, p=0.374) (Figure 4; Appendix B). Similarly, there was a weak 
negative correlation between proximal tibia aBMD and serum 25(OH)D level (r=-0.197, 
p=0.242), which was not significant (Figure 5; Appendix B). At the 4% tibia trabecular site, no 
correlation was found between serum 25(OH)D level and trabecular vBMD (r=-0.003, p=0.990) 
(Figure 6; Appendix B). Additionally, at the 66% tibia cortical site no correlations were evident 
between serum 25(OH)D and cortical vBMD (r=-0.018, p=0.923) (Figure 7; Appendix B) or 
cortical thickness (r=-0.066, p=0.716) (Figure 8; Appendix B). Knowing serum 25(OH)D level 
did not add significant value for predicting any of the assessed bone quality outcomes.   
 
 
Characteristic OR 95% CI P value 
Vitamin D Assessed in Winter Months 6.3 1.30 – 30.53 0.022* 
Female Gender 1.1 0.22 – 5.86 0.881 
Age 0.92 0.847 – 0.995 0.038* 
Duration of Injury 0.98 0.914 – 1.048 0.532 
Motor Complete Injury 1.1 0.26 – 5.23 0.860 
Paraplegic 3.0 0.636 – 14.15 0.165 
Not on a Vitamin D Supplement 10.5 1.014 – 108.68 0.049* 
Not on a Calcium Supplement 7.1 1.121 – 45.52 0.038* 
Not on a Multivitamin 0.97 0.232 – 4.042 0.966 
Not on a Bisphosphonate 2.7 0.613 – 11.60 0.191 
Currently Smoking 2.4 0.531 – 11.12 0.253 
Hyperparathyroidism 0.53 0.09 – 3.178 0.490 
Obesity 1.2 0.282 – 4.84 0.832 
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4.6.0. SECONDARY HYPERPARATHYROIDISM 
Fifteen percent (95% CI, 4.8 – 25.2) of the population demonstrated serum intact PTH levels 
above the upper limit of the normal range (≥ 7.0 pmol/L), with the remaining 85% (95% CI, 72.8 
– 97.2) exhibiting serum intact PTH in the normal range (1.6 – 6.9 pmol/L). The mean (SD) 
serum intact PTH level within the normal hormonal range was 3.99 (±1.44) pmol/L (95% CI, 3.4 
– 4.6) with levels ranging between 1.9 and 6.9 pmol/L, whereas the mean (SD) serum intact PTH 
level in the group with hyperparathyroidism was 9.64 (±2.63) pmol/L (95% CI, 6.4 – 12.9) with 
levels ranging from 7.7 to 13.6 pmol/L. Figure 9 illustrates the scatter of the serum intact PTH 
levels for all participants. 
Figure 9. Serum intact PTH (pmol/L) for all participants (n=33)  illustrating those in the normal range and 
 those with hyperparathyroidism.  
 
The mean (SD) of serum ionized calcium for the whole cohort was 1.23 (±0.041) 
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serum ionized calcium below the normal and two had serum ionized calcium levels near the 
lower end of the normal range, which is from 1.17 – 1.33 mmol/L, with only one of these 
participants demonstrating secondary hyperparathyroidism. 
 
4.7.0. RELATIONSHIP BETWEEN PTH AND 25(OH)D AND CALCIUM 
Prediction of serum intact PTH levels with known serum 25(OH)D levels could be done with 
some certainty in the current study group of individuals with chronic SCI. There was a moderate 
inverse correlation between serum intact PTH and serum 25(OH)D levels, approaching 
significance (r=-0.327, p=0.068) (Figure 10).  Additionally, there was a weak negative, non-
significant correlation between serum ionized calcium and serum intact PTH (r=-0.227, p=0.204) 
(Figure 11; Appendix B).   
































y = -0.022x + 6.791  
R
2
 = 0.1069 
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4.8.0. RELATIONSHIP BETWEEN PTH AND BONE QUALITY OUTCOMES 
There were no significant correlations between the assessed bone quality outcomes and PTH. A 
moderate negative correlation between 66% tibia cortical thickness and serum intact PTH was 
evident, and approached significance (r=-0.353, p=0.071) (Figure 12). There were weak 
negative, non-significant correlations between 4% tibia trabecular vBMD and serum intact PTH 
(r=-0.293, p=0.123) (Figure 13; Appendix B) and between 66% tibia cortical vBMD and serum 
intact PTH (r=-0.243, p=0.222) (Figure 14; Appendix B). There were no evident associations 
between distal femur aBMD and serum intact PTH (r=0.005, p=0.980) (Figure 15; Appendix B), 
or between proximal tibia aBMD and serum intact PTH (r=-0.054, p=0.774) (Figure 16; 
Appendix B). 
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y = -0.127x + 3.898 
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 = 0.124 
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4.9.0. POST HOC ANALYSES WITH SERUM C-TELOPEPTIDE 
There was a significant positive correlation between serum C-Telopeptide, a biomarker of bone 
resorption, and serum intact PTH (r=0.509, p=0.016) (Figure 17). There was no relationship 





































A cohort of 45 adult individuals with chronic SCI were evaluated regarding their serum 
25(OH)D level, serum intact PTH level, and the relationships of these hormones with indicators 
of lower extremity bone quality; including aBMD, vBMD and cortical thickness measurements. 
Sixty-two percent of the study population with chronic SCI, a greater proportion than expected, 
presented with serum 25(OH)D  levels in the optimal range (≥75 nmol/L). Additionally, having 
25(OH)D assessed in the winter months, not being on a calcium supplement, not being on 
vitamin D supplement and being younger may be important risk factors for identifying 
individuals at highest risk for suboptimal levels of 25(OH)D. Although no relationships between 
25(OH)D or PTH and any of the indicators of lower extremity bone health were demonstrated, 
there was a trend towards an inverse relationship between 25(OH)D and PTH, suggesting that 
vitamin D status could still be an important part of bone health in the chronic years of SCI 
through PTH levels.  
 
5.2.0. INTERPRETATION 
5.2.1. VITAMIN D STATUS 
The current evaluation of vitamin D status in individuals with chronic SCI is representative of a 
group of males and females with complete or incomplete injuries and with varying levels and 
years post-injury. Thirty-eight percent of the chronic SCI population studied demonstrated 
suboptimal 25(OH)D levels (<75nmol/L). Further, the median of the serum 25(OH)D level in the 
suboptimal and optimal groups were 57 nmol/L and 102 nmol/L, respectively, identifying that 
many of those in the suboptimal range are much lower than the optimal cut-off of 75nmol/L. 
48 
 
Although one previous report of vitamin D status in the SCI population similarly identified 
greater than 32% of participants to have suboptimal serum 25(OH)D levels (29),  more recent 
work has suggested that as much as 96% of individuals with SCI have suboptimal vitamin D 
levels (69; 90). Bauman (29) and colleagues were first to report vitamin D status in SCI however 
may have underestimated the true prevalence of vitamin D deficiency. They determined about 
32% of their population with SCI to have levels in the deficient range; however deficiency was 
defined as 40nmol/L. It is now generally understood that for optimal bone health benefits serum 
25(OH)D levels should be above 75nmol/L; which is necessary for adequate suppression of PTH 
release and stimulation of intestinal calcium absorption. More recently, Oleson (90) and 
colleagues identified 96% of participants with chronic SCI and less than 55 years of age to be 
deficient, defined as <80nmol/L. However, their evaluation of vitamin D status excluded 
individuals consuming greater than 400IU of vitamin D per day; indicating that the true 
proportion of the chronic SCI population may be less than 96% if those taking supplements 
exceeding 400IU of vitamin D were included in the analysis. Another more recent study of 
vitamin D status in individuals with SCI, using the updated definition of deficiency (<75nmol/L), 
found 93% to have inadequate 25(OH)D levels (69). This study was limited to an inpatient 
rehabilitation setting of acutely injured patients. The 25(OH)D levels were assessed at the time 
of admission to rehab and therefore cannot be applied to out-patients in the chronic years after 
injury. Although a high prevalence of vitamin D deficiency in individuals with SCI has been 
suggested, gaps in the literature remain for community dwelling males and females at varying 
times post injury. The current study demonstrates vitamin D status in a group of males and 
females with chronic SCI, including a diverse range of impairments. Given many of the current 
study population were being monitored annually regarding their bone health and being treated 
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for low BMD at the time of data collection, the true prevalence of vitamin D deficiency in the 
SCI population may be higher than estimated, and may be closer to that in the non-SCI 
population. In the non-SCI post-menopausal osteoporotic population, 64% of people have been 
shown to have suboptimal serum 25(OH)D levels (94).  Of the 38% found to have suboptimal 
serum 25(OH)D in the current study, 73% reported being on a vitamin D supplement, 
demonstrating that even in those being treated with supplements, serum 25(OH)D concentrations 
are not reaching optimal levels and indicate that greater supplementation and additional 
monitoring is necessary. Additionally, a major source of acquiring vitamin D is through sun 
exposure, therefore quantifying the amount of sun exposure in participants may increase our 
understanding of vitamin D status in this population. The current work confirms that vitamin D 
deficiency is prevalent and a concern in the chronic SCI population, however the proportion of 
those with suboptimal vitamin D levels may be higher than estimated. Supplementation alone 
may not ensure optimal levels suggesting serum 25(OH)D should be monitored over time in each 
person with an SCI, with supplements prescribed on an individual basis.  
 Correlates of suboptimal vitamin D status exist in the chronic SCI population and should 
be considered when evaluating vitamin D status and identifying those at higher risk of 
deficiency. Factors that influence the risk of having suboptimal vitamin D status in the non-SCI 
population include: obesity (88), living at latitudes where the wintertime zenith angle of the sun 
is not sufficient to initiate synthesis of 25(OH)D in the skin (52; 95), older age (49; 96), high 
skin pigmentation (62; 97), having a diagnosis of osteoporosis (98), and the techniques used to 
measure vitamin D (61). Results of the current study identified correlates of suboptimal vitamin 
D status to be: vitamin D status assessed in the winter months, not taking a vitamin D 
supplement, not taking a calcium supplement and younger age.  More specifically, with respect 
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to the associated increased risk of deficiency with measurements assessed in the wintertime, of 
the 12 25(OH)D measurements obtained in the winter months, 8 were in the suboptimal range, 
whereas 6 out of the 27 measurements obtained in the summer months were in the suboptimal 
range. With cautious regard to the small sample of measurements obtained in the winter months, 
it is suggested that in the SCI population supplement use and increased dietary intake of vitamin 
D may be necessary to decrease the odds of having suboptimal vitamin D levels. Additionally, it 
may seem obvious that if not taking a vitamin D supplement, one would be at an increased risk 
of being vitamin D deficient; however this finding emphasizes that individuals with SCI are not 
acquiring enough vitamin D through sun exposure or in their diet to put them in the optimal 
vitamin D range for health benefits. Opperman (71) reported vitamin D and calcium supplement 
use to be in the top three supplements used in the SCI population, and given that vitamin D is 
often prescribed in conjunction with calcium supplementation to maximize the calcium 
absorption, it is not surprising that those not taking calcium supplements are at an increased risk 
of vitamin D deficiency. In a larger sample, assessing the odds of suboptimal vitamin D levels in 
those not taking calcium supplements, when the variance associated with not taking a vitamin D 
supplement is removed, would help discern whether or not taking a calcium supplement is truly 
associated with an increased risk of vitamin D deficiency. Interestingly, in the evaluated group of 
individuals with SCI, being younger was associated with an increased odds of suboptimal serum 
25(OH)D levels. In the non-SCI population, declining bone health is generally problematic for 
older individuals, and therefore younger people may not be as aware of the importance of 
vitamin D to their bone health. Perhaps younger individuals with SCI are unaware that their bone 
health declines post-injury regardless of their age, and therefore may not be concerned with 
vitamin D supplementation. Alternatively, vitamin D metabolism in younger individuals with 
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SCI may be different to that of older individuals with SCI. Decreased renal function, common 
post-SCI, and history of medication use may affect older and younger individuals differently. 
Repeat results in a much larger sample is necessary to warrant further investigation into the 
mechanism in which younger age increases the odds of vitamin D deficiency in the SCI 
population. Future studies evaluating the vitamin D status in individuals with chronic SCI should 
also assess correlates of vitamin D deficiency to identify those at highest risk for having 
suboptimal vitamin D status. The current results suggest that assessing vitamin D status in the 
winter months, not taking a vitamin D supplement, not taking a calcium supplement and younger 
age should be factors targeted when evaluating risk of vitamin D deficiency in individuals with 
chronic SCI, and should be used in future models predicting deficiency.    
 
5.2.2. RELATIONSHIP BETWEEN 25(OH)D AND BONE QUALITY OUTCOMES 
No relationships were observed between serum 25(OH)D and bone health outcomes in our 
cohort of individuals with chronic SCI. In the non-SCI population, hip BMD, a common site of 
fracture, is shown to be significantly correlated with serum 25(OH)D in women over 60 (30). 
Similarly, in men over the age of 55 years, 25(OH)D level is identified as a significant 
determinant of hip BMD (99). Further, an intervention trial with 400 IU of vitamin D and 1000 
mg of calcium supplementation per day, in post-menopausal women, demonstrated increased hip 
BMD compared with a placebo group (100). Due to the proposed relationships between vitamin 
D and bone loss in the non-SCI population, vitamin D has been suggested to be a modifiable 
factor potentially affecting BMD in the chronic stages of SCI (31). To date, few studies identify 
if vitamin D deficiency is actually prevalent in individuals with SCI (69; 90), and no studies have 
identified what the relationship between 25(OH)D and bone quality is in the SCI population.  
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Previous work regarding vitamin D and bone health in individuals with SCI has evaluated the 
effect of vitamin D supplementation on serum vitamin D status (72), as well as the effect of 
vitamin D analog supplementation on lower extremity aBMD (73).  The current study 
demonstrated 38% to have suboptimal vitamin D levels. Interestingly, even though a significant 
proportion of the population studied demonstrated suboptimal vitamin D levels, and a large 
proportion of the study sample had aBMD values measuring below the fracture threshold, there 
were no significant relationships between 25(OH)D levels and bone quality outcomes. It is 
possible that the reason no relationship was observed between bone quality outcomes and 
25(OH)D is because all the other factors known to influence the variation of bone loss in the SCI 
population were not adjusted for in the current analysis, due to the small sample size. Factors 
known to increase the risk of lower extremity fractures or low BMD following an SCI include: 
BMI less than 19 (6), having a duration of injury greater than 10 years (16), being female (16), 
having a motor complete injury (101), being paraplegic (17), having secondary 
hyperparathyroidism (31), not being treated with a bisphosphonate (102) and excessive cigarette 
smoking (103; 23).  Therefore, the true relationship between 25(OH)D and bone quality may be 
masked by the variation in bone density due to, for example, having a motor complete injury. 
Additionally, the relationships between 25(OH)D and bone quality outcomes may be better 
elucidated if vitamin D status is known over a period of time; conceivably it is not vitamin D 
status today that is associated with BMD today. The serum measurement of vitamin D at one 
time may not be representative of lifetime vitamin D status, and may be exceptionally high or 
low depending on factors such as history of vitamin D supplement use, sun exposure and skin 
pigmentation, as well as season of measurement. In 577 men and 1335 women studied all across 
Canada, suboptimal (<75 nmol/L) vitamin D levels were evident in about 60% of both men and 
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women in the spring and up to 78% in the winter (104). Further, in 351 young men and women 
studied prospectively in the Toronto area, mean serum 25(OH)D levels were lower in the winter 
at 38.4 nmol/L compared to 54.4 nmol/L in the fall; serum 25(OH)D levels in both the fall in 
winter were suboptimal, however levels were much lower in the winter (105). Similar to 
previous work, the current evaluation of factors associated with vitamin D deficiency found 
supplement use and season of assessment to be significantly associated with suboptimal vitamin 
D levels. Prospective study of the relationship between serum 25(OH)D and bone health 
outcomes over more time points would be useful in evaluating the true relationships between 
these variables. Future investigations should adjust for correlates of bone health and factors 
associated with vitamin D deficiency in the SCI population to demonstrate the true association 
between vitamin D and bone quality. 
 
5.2.3. SECONDARY HYPERPARATHYROIDISM AND 25(OH)D AND CALCIUM 
Secondary hyperparathyroidism, induced from low serum calcium levels, may be associated with 
low vitamin D levels in chronic SCI. Vitamin D aids in the suppression of excessive PTH 
secretion by increasing serum ionized calcium levels through enhanced intestinal calcium 
absorption. Based on the known function of vitamin D in maintaining serum calcium levels, it is 
expected that in a population without known primary hyperparathyroidism, lower serum 
25(OH)D levels would be associated with higher PTH levels, and that higher PTH levels would 
also be associated with lower serum ionized calcium levels. Identifying such a relationship 
provides evidence that serum vitamin D level could be an important mediator in PTH stimulated 
resorption of calcium stores in bones. An inverse relationship between serum 25(OH)D and 
intact PTH has been demonstrated in older persons with no SCI (106; 107). In addition, serum 
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PTH has been shown to fluctuate seasonally with serum 25(OH)D, but in the opposite direction 
(108), further demonstrating the importance of vitamin D in maintaining normal levels of PTH 
and minimizing the release of calcium stores from bones. In a group of individuals with long-
standing SCI, a significant negative correlation was demonstrated between serum 25(OH)D and 
PTH illustrating that low vitamin D could be implicated in the bone loss seen in the years 
following a SCI (29). The current study demonstrated about 15% of the population to have serum 
PTH above the upper limit of normal. Given that 38% of the population had serum 25(OH)D 
levels in the suboptimal range, it is somewhat surprising that the number with secondary 
hyperparathyroidism is not higher. However, the cross sectional design of this study, and the 
unknown duration that these individuals have been in the suboptimal 25(OH)D range, could 
influence the number of people demonstrating hyperparathyroidism. Additionally, the threshold 
of vitamin D needed to maximally suppress PTH release varies in the literature from 30nmol/L 
to 99 nmol/L (53; 109; 110; 111; 112; 113), and may be different in the SCI population than the 
non-SCI population. Furthermore, the degree of neurologic impairment in those with SCI has 
been associated with PTH suppression (114), hence grouping all impairments may be why closer 
to equal proportions of suboptimal vitamin D and hyperparathyroidism were not demonstrated. 
The current study demonstrates the expected trend between serum 25(OH)D levels and serum 
intact PTH. Additionally, the trend towards an inverse relationship between serum intact PTH 
and ionized calcium was also demonstrated. Furthermore, a significant positive relationship was 
seen between serum C-Telopeptide and serum intact PTH; identifying that higher PTH levels are 
associated with more bone resorption. In this group of individuals with SCI, lower levels of 
25(OH)D likely contribute to decreased calcium absorption and increased PTH secretion. 
Further, adequate calcium and vitamin D are important in those with chronic SCI for bone health 
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maintenance through minimizing PTH stimulated bone resorption. To better understand the 
relationship between serum intact PTH and serum 25(OH)D, particularly in individuals with 
known renal dysfunction, measurement of 1,25(OH)2D would help identify if  low 25(OH)D is 
truly leading to the high PTH levels. Based on the relationships demonstrated in the current study 
it is suggested that in those with chronic SCI the serum 25(OH)D threshold for maximum 
suppression of PTH is around 125 nmol/L. With a larger sample of individuals with chronic SCI, 
it would be interesting to evaluate at which level of 25(OH)D the PTH plateaus, aiding in 
identifying whether the optimal 25(OH)D level in the SCI population matches the currently used 
standard of 75nmol/L or is closer to the 125 nmol/L identified in the current cohort of males and 
females with chronic SCI. 
 
5.2.4. RELATIONSHIP BETWEEN PTH AND BONE QUALITY OUTCOMES 
Identifying a relationship between PTH and bone quality outcomes would provide evidence that 
the vitamin D-PTH axis is a modulator of bone health in SCI. No correlation was found between 
PTH and aBMD parameters. One explanation for this could be that DXA is not sensitive enough 
to distinguish differences in bone health due to differences in PTH. Cortical and trabecular 
compartments of bone cannot be separated when analyzing DXA scans. Hyperparathyroidism, a 
common complication of chronic kidney disease, has been shown to influence cortical measures 
of bone in the non-SCI population (115). Further, in a group of men and women with chronic 
kidney disease, cortical vBMD, thickness, and area were associated with fractures (83). In 
chronic kidney disease, the renal hydroxylation of 25(OH)D decreases regardless of the amount 
of circulating 25(OH)D (116), which decreases vitamin D assisted intestinal calcium absorption 
and thereby increases the stimulation of PTH secretion. Although fractures in the SCI population 
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have mostly been attributed to trabecular bone loss (13), to fully understand the impact of 
suboptimal vitamin D status for bone quality in SCI, it is important to identify any association 
between PTH and cortical bone parameters given prior implications on cortical bone in 
populations with hyperparathyroidism. In the current study there were weak negative, non-
significant correlations found between PTH and vBMD at both the 4% and 66% sites; however, 
PTH was shown to moderately correlate in the negative direction with cortical thickness, and 
approached significance. Results from the current study suggest that higher levels of PTH may 
be associated with smaller cortical thicknesses. With a larger sample, allowing for control of 
other factors that contribute to the bone loss post-SCI, certain subgroups of the SCI population 
with PTH associated low cortical bone parameters could be distinguished. The results, although 
not what was completely expected based on previous literature, indicate that the vitamin D-PTH 
axis is important to bone health in the SCI population. Perhaps the primary implication of low 
vitamin D and high PTH in the SCI population is linked to cortical thickness, and while not 
regarded as the best indicator of fracture prediction in this population, it does contribute to 
overall bone health.  
 
5.3.0. LIMITATIONS 
The current study has limitations that must be considered carefully when making conclusions. 
The cross-sectional design of the current study did not allow for any conclusions regarding the 
chronology of any observations made, nor causality of the relationships. The results cannot 
distinguish between newly occurring or longstanding suboptimal vitamin D levels, low aBMD, 
low vBMD, or cortical thickness measurements. Cross-sectional study design is particularly 
problematic when assessing bone health outcomes due to the length of time of the bone turnover 
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cycle. The physiological process of bone resorption could be initiated months before lower bone 
density is detected on a bone density scan, therefore, the serum 25(OH)D level at the time of 
BMD measurement may not reflect the true relationship between it and the bone quality 
parameters assessed. The current study design and exploratory correlational analyses were 
employed to identify the potential importance of serum 25(OH)D level for evaluating bone 
health in the SCI population. To establish an actual causal relationship between vitamin D 
deficiency and bone health outcomes, it would have to be demonstrated that variation in the bone 
health outcomes could only be due to the variation in serum 25(OH)D level, and that no other 
variables are causing them to co-vary. Additionally, assessments of vitamin D status over time 
could reveal the importance of vitamin D to bone health in the SCI population. 
 All potential correlates of poor bone quality or low vitamin D levels could not be 
accounted for, as well the sample size achieved did not allow for correlates of poor bone health 
outcomes, or factors known to influence vitamin D status to be controlled for. Some types of 
drugs taken by participants in the current study, such as anticonvulsants, can effect vitamin D 
metabolism in the body, and thus affect the apparent relationships observed. Serum 25(OH)D 
levels were shown to decline below normal after six months of taking anticonvulsant drugs 
(117). Additionally, calcium and vitamin D supplements consumed in this population may vary 
from what was reported by participants, depending on adherence to supplement use and their 
dietary intake. Better assessment of calcium and D supplements use could change the risk factors 
associated with suboptimal vitamin D levels. Other factors that may influence vitamin D status 
or bone health outcomes, that were not assessed include: sun exposure and sex hormone levels. 
Quantifying the amount of sun exposure is difficult and depends on other factors such as: time of 
day, whether sunscreen was used, skin exposure and pigment, as well as others. Although sun 
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exposure could not be included in the analysis, we attempted to account for some aspect of this 
factor by looking at season as a risk factor. Low sex steroid hormones have been significantly 
associated with faster rates of BMD loss in older men with no SCI (118). Additionally, it has 
been suggested that 60% of men with SCI have low testosterone levels (119). Future studies 
evaluating the relationship between bone parameters and vitamin D should evaluate the 
interaction of sex steroid hormone levels. To infer that the relationships between 25(OH)D and 
the bone health outcomes assessed in the current study are not masked, attenuated, or amplified, 
the variance associated with all the variables known to affect bone health  outcomes and serum 
25(OH)D would have to be controlled for in a much larger sample of individuals with chronic 
SCI.  
The results of the current study may not be generalizable to all individuals with SCI. 
Many of the participants were recruited from physician referral at the bone clinic in outpatient 
services at the Toronto Rehabilitation Institute, thereby introducing some degree of recruitment 
bias. As a result, many of the participants were currently on treatment for low bone mineral 
density. Participants had been prescribed treatments including: bisphosphonte drugs, calcium and 
vitamin D supplements, and exercise. In a group of men with motor complete SCI’s treated with 
bisphosphonates, BMD decline was demonstrated to slow over a 2 year period (91). However, 
prevalence of suboptimal 25(OH)D in a non-SCI population was shown to be independent of 
whether or not persons were on prescription osteoporosis treatment (58). Therefore, although the 
serum 25(OH)D status of our population may not be affected by bisphosphonate use, the true 
relationship between 25(OH)D and bone health measures may be masked in those participants 
taking bisphosphonate drugs. Additionally, our participants had an average time post injury of 
about 15 years. We know that bone loss in this population is considerably different in the first 
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few years post injury when compared to many years post injury (23) therefore no conclusions 
can be made about the relationship between vitamin D status and BMD in the early years post-
injury. Some participants included in our study were unable to have their aBMD measured in the 
knee region as a result of having hardware from a previous fracture, likely due to low aBMD.  
Therefore, we may not have captured well the relationship between 25(OH)D and bone quality 
measures in those with severe enough bone loss to cause fracture. Furthermore, three-quarters of 
the population studied were male and two-thirds of the population had motor complete injuries. 
Although the study population may correctly represent the demographics of the SCI population, 
it did not allow for subgroup analysis to distinguish who specifically in the SCI population may 
have an association between bone quality and vitamin D levels. The current study mainly 
consisted of older individuals, the average age at data collection was 51 years, however many 
individuals have their SCI when they are quite young; consequently, there is an 
underrepresentation of young people with SCI. Although there are some factors affecting the 
external validity based on the demographics of the population studied, there is no other literature 
evaluating vitamin D status and the relationships between serum 25(OH)D and bone quality in a 
well-represented cohort of individuals with SCI. 
One final potential source of bias comes from measurement uncertainty. It is suggested 
that serum 25(OH)D assays can measure vitamin D levels 10% lower or higher than the true 
serum level (120). Therefore, someone measuring near the optimal vitamin D cut-off level may 
be misplaced in either the optimal or suboptimal group, either overestimating or underestimating 
the number of participants presenting with optimal vitamin D levels. In the current study all 
samples were measured at the same lab, with the same technique, in attempt to limit bias 




The prevalence of vitamin D deficiency and the relationship between serum 25(OH)D or PTH 
and bone quality has not been well evaluated in individuals with chronic SCI. About 40% of the 
population studied demonstrated suboptimal vitamin D levels, despite a large proportion taking 
vitamin D and calcium supplements. Identified risk factors for suboptimal vitamin D levels in the 
SCI population include: assessing vitamin D in the winter months, not taking vitamin D or 
calcium supplements, and being younger; suggesting that many individuals with SCI are not 
obtaining sufficient quantities of vitamin D in their diet or through supplementation, particularly 
in the winter months. The observed trend towards negative correlations between PTH and 
25(OH)D and between PTH and ionized calcium identify that disruption in the vitamin D-PTH 
axis could be important to the bone loss seen in the chronic SCI population. Further, a trend 
towards a negative association between PTH levels and cortical thickness measures was 
observed. Serum 25(OH)D level, therefore may be important for bone health in the SCI 
population through maintaining adequate serum calcium and normal PTH levels. The current 
study adds unique value to vitamin D and bone quality research in SCI. The current study 
provides the framework for future investigations of the relationships between 25(OH)D and bone 
quality in SCI, with high external validity. Ultimately, identifying a relationship between a 
disrupted Vitamin D – PTH axis and bone quality could contribute to the development of an SCI 
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RECRUITMENT AND DATA COLLECTION 
 
1. Physician referral form 
2. Letter of invitation 
3. Recruitment script 
4. Telephone screening form 
5. Information and consent 
6. Additional screening forms 
7. Past medical history 
8. Disease/conditions affecting BMD 
9. Current health status 
10. Concurrent medications 
11. Health demographics 
12. Fracture ascertainment questionnaire 
13. Food frequency questionnaire 
14. Penn Spasm Frequency Scale 






















RESEARCH:  Bone Quality in Individuals with Chronic Spinal Cord 
Injury 
 
Background: A cohort of 80 adult men and women, two years post SCI, will be established. Data collected 
will include: medical history; bone density (BMD) and body composition; tibia volumetric BMD, bone 
geometry, muscle area and trabecular structure; and x-ray reports to verify fractures (if any). Data will be 
collected at 6 month intervals over a 24 month period.  This research will form the basis for studies of 





Patient has verbally consented to the above personal health 
information being forwarded to a research team member and being 









Please forward to Lindsie Robertson (x6301, room 206-D)  
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  Bone quality in individuals with chronic spinal cord Injury 




















Dear  <Name>: 
 
 
You are being asked to take part in a research study called “Bone quality 
in individuals with chronic SCI”. Myself and other researchers at McMaster 
University, the University of Waterloo, University of Toronto and the Toronto 
Rehabilitation Institute are conducting the study.  The Canadian Institutes of 
Health Research are funding this study (www.cihr-irsc.gc.ca). The purpose of the 
study is to examine the bone health of men and women with chronic spinal cord 
injury.  
If you agree to take part in the study, you will be asked to have your bone 
density measured once a year for 2 years.  You will also be asked to report your 
past and current medical history and medications, followed by a brief 
examination of your sensation and muscle activity. You will participate in two 
types of bone density scans in the study; one at Lyndhurst and one at McMaster 
University. Transportation to McMaster University will be provided.  The overall 
time commitment for the study is 10-15 hours over the 2 year period.  This 
includes three visits to Lyndhurst (2-3 hours each) as well as three visits to 
McMaster (30 minutes each) and five telephone follow-up calls (30 minutes 
each).  All participants will receive a $40 honorarium at the 0 (start), 1 year and 2 
year time points. 
At some point in the next two weeks you will receive a telephone call from 
a research assistant. The assistant will ask you if you are interested in 
participating in this study. If you are not interested, you can tell the assistant at 
this time. If you would prefer not to have the assistant call you at all, please call 
(416) 597-3422, extension 6301. Leave a message with our research 
Primary Investigators: 
Dr. Lora Giangregorio 
Dr. Catharine B. Craven 
Co-investigators: 
Dr. A. Papaioannou 
Dr. M. Popovic 
Dr. L. Thabane 
Dr. N. McCartney 
Dr. J.D. Adachi 
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coordinator, Lindsie Robertson, saying that you would prefer not to be contacted.   
Alternatively, you can also e-mail robertson.lindsie@torontorehab.on.ca.  
It is important for us to know if people who participate in the study are 
very different from people who choose not to participate. If you choose not to 
participate, the research assistant will ask you if you mind answering a few brief 
questions, such as your age or whether you have ever broken a bone before. 
Your name will not be stored with this information. You can choose not to answer 
these questions if you wish. 
If you decide to participate in the study, all information you provide will be 
confidential. Your name will not appear on any forms. You can stop participating 
at any time without having to give a reason.  A decision not to volunteer or to 
withdraw from the study after you have enrolled will not have any impact on the 
care you receive at Lyndhurst. If you have any questions about the study you can 
contact Lindsie Robertson at the number listed above or Dr. Cathy Craven at 
(416) 597-3422 extension 6122.  
Your contribution to this research will help us better understand who is at 
risk for bone loss and broken bones. We eventually want to understand better 
ways to diagnose and prevent broken bones among people with spinal cord 






insert physician name here 
 
This study has been reviewed and received ethics clearance through the Office of Research 
Ethics at the University of Waterloo, the Research Ethics Board at the Toronto Rehabilitation 
Institute and the Research Ethics Board of Hamilton Health Sciences/McMaster University 
Faculty of Health Sciences.. If you have any questions regarding your rights as a research 
participant, you may contact: Dr. Gaetan Tardif of Toronto Rehabilitation Institute Research 
Ethics Board at (416) 597-3422 x 3730 or Dr. Susan Sykes University of Waterloo Research 
Ethics Board at 519-888-4567, x 36005, ssykes@uwaterloo.ca or Deborah Mazzetti of Office of 
the Chair of Hamilton Health Sciences/Faculty of Health Sciences Research Ethics Board at 




Telephone Script for Recruitment  
“Hello, my name is ___________ and I am calling from Lyndhurst Centre about a research study 
that is being conducted by Dr. Craven at Toronto Rehab, Dr. Lora Giangregorio at the University 
of Waterloo and several other researchers. Did you receive a letter in the mail about it? (Did Dr. 
______ speak to you about this study?)” 
If YES, continue with script. If NO, tell them you can mail the letter and let them 
read it and then call back, or you can explain it now. 
“It is a research study that will explore bone health among individuals with spinal cord injury, 
and determine how bone health changes over time. Individuals who participate in the study will 
be asked to report their medical history and participate in a medical exam and bone density tests 
once a year for two years. An honorarium for travel expenses will be provided. I can explain the 
study in more detail if you would like to hear more. Does this sound like something you might be 
interested in?” 
If YES, continue with script. If NO, move to refusal questionnaire script. 
“Before I go into more detail explaining the study, I would like to know if you fit the criteria for 
being in the study. I have a few questions I would like to go through with you to determine if you 
are eligible. Do you have a few minutes to do this now?” 
If YES, continue with pre-screening. If NO, ask if there is a better time for you to call. 
Record this time. 
“Before I begin, let me remind you that you can decide not to answer any questions or decide not 
to be in the study at any time.” 
Begin filling out pre-screening form.  
If this person is NOT eligible for the study, thank them for taking the time to answer your 
questions. Explain that they do not fit all of the criteria for entering the study. 
If they ARE eligible for the study, thank them for taking the time to answer your questions. 
Indicate they may be eligible, and you would like to tell them more about the study. 
"As I mentioned before, the study will explore bone health among individuals with spinal cord 
injury. We are interested in finding out if people who have a chronic spinal cord injury continue 
to lose bone, and use new technologies to assess their bone health. The study involves coming to 
Lyndhurst centre for one visit per year for three years, as well as one visit to McMaster 
University each year. Each annual visit to Lyndhurst will take approximately 2 hours during 
which; you will complete a medical history and undergo a short examination, and have your 
bone density measured. Each annual visit to McMaster University will take 30 minutes; you will 
have two bone density scans done on your lower leg (shin). We can arrange for transportation to 
McMaster for you. We also provide a $40 honorarium each year when you complete your visit to 
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cover any additional costs you may have. Do you have any questions so far?” 
If YES, answer any questions. If NO, continue with pre-screening. 
“If you think you might be interested in participating in the study, the next step is to have you 
come to Lyndhurst to learn about the study in more detail. If you change your mind and do not 
want to participate, you can decline participation at any time. Declining will have no impact on 
the health care you receive at Lyndhurst. If you are still interested in participating we will have 
you read the information package and complete a consent form before your first assessment. The 
information and consent process will take one hour, and the assessments will take approximately 
2 hours. We will then arrange for you to go to Hamilton for your visit there. Do you think you 
might be interested in participating in the study?” 
If YES, schedule a date/time. If NO, continue with refusal questionnaire. 
We want to inform you that this project has been reviewed and received ethics clearance through the University of 
Waterloo's Office of Research Ethics and the Toronto Rehab Research Ethics Board. 




Assessors Initials:  
 






Gender:  M   F    
 
If potential participant is eligible for the study, arrange for a visit to Lyndhurst to complete information and 
consent form and first testing visit (if consent is provided). 
Inclusion Criteria Yes No Comments 
1. Participant is ≥18 years of age     
2.  Participant is able to understand instructions in English.    
3. 
“What was the cause of your spinal cord injury?” 
Potential participant has a neurological impairment 
secondary to a spinal cord injury of sudden onset (<24 





“When did you have your spinal cord injury?” 
Potential participant’s spinal cord injury occurred at least 
24 months prior to screening. 
   
5.   
“Do you know if you have or have had any conditions 
that might affect your bones, such as cancer or liver 
disease?” Potential participant has no secondary causes 
of osteoporosis. 
   
6.   
“Are you willing to attend three visits to Lyndhurst and 
three visits to McMaster University over the course of 
two years?” 
Potential participant is willing to attend 3 visits to 
Lyndhurst & McMaster. 
   
Telephone Screening Form 
Y Y Y Y M M D D 
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Title of Study: Bone Quality in Individuals with Chronic Spinal Cord Injury 
Primary Investigators:  Dr. Lora Giangregorio and Dr. Catharine B. Craven 
Co-investigators: Dr. Papaioannou, Dr. Popovic, Dr. Thabane, Dr. McCartney and 
Dr. Adachi 
Student Investigator: Kayla Hummel, Dept. of Kinesiology, University of 
Waterloo 
Sponsor: Canadian Institutes of Health Research 
 
 
You are being invited to participate in a research study. To decide whether or not 
you want to be a part of this research study, you should be aware of what is 
involved and the potential risks and benefits. This form gives detailed information 
about the research study, which will be discussed with you. Once you understand 
the study, you will be asked to sign the form at the end of this information letter if 
you wish to participate. If you are not able to sign the form but are able to provide 
verbal consent, it will be documented by the person obtaining consent. Please take 
your time to make your decision. Feel free to discuss it with your friends and 
family, or your family physician. 
 
WHY IS THIS RESEARCH BEING DONE? 
 
Individuals with spinal cord injury (SCI) often experience bone loss. Bone loss can 
cause a person to be more likely to break a bone in the future. We are conducting 
this study to examine in more detail the bone loss that occurs after SCI.  
 
WHAT WILL I BE ASKED TO DO IF I DECIDE TO TAKE PART IN THE 
STUDY? 
 
This study will involve 10-15 hours of your time over a 2 year period.  If you 
decide to participate in the study, we will ask you to do the following things: 
Primary Investigators: 
Dr. Lora Giangregorio 
Dr. Catharine B. Craven 
Co-investigators: 
Dr. A. Papaioannou 
Dr. M. Popovic 
Dr. L. Thabane 
Dr. N. McCartney 




Visit to Lyndhurst (Toronto) or Chedoke (Hamilton) 
 Complete a medical history that asks questions about your injury 
characteristics as well as your past and current medical health, medications 
and lifestyle. You may be asked to have an ASIA (American Spinal Cord 
Injury Association) impairment exam, which tests your sense of touch and 
your sense of movement, if we do not have record of an exam for you. This 
will take approximately 45 minutes.  
 On your first visit to Lyndhurst, you will be asked to provide a blood 
sample. The blood sample will be used to measure protein markers of bone 
metabolism and vitamin D levels in your blood. The blood sample will be 
draw by a trained phlebotomist by inserting a needle in a vein in your arm.  
We will take about two tablespoons of blood.  
 Participate in 1 set of 6 bone density scans. Bone density scans are x-rays 
that measure how much bone mineral you have in certain bones. Individuals 
with low amounts of bone mineral may be at increased risk of fracture. The 
scans will be taken of your hips, above and below your knee, your spine and 
your whole body. During the scans you will be transferred to a scanning 
table. If you are not able to transfer yourself, we will use a special lift 
device. The scanning will take approximately 60 minutes. 
 Complete some questionnaires by phone three days after your visit.  The 
questionnaires will ask you questions regarding your physical activity and 
diet.  This telephone call will last approximately 30 minutes. 
 
Visit to McMaster  
 Participate in a second visit at McMaster University Medical Centre for a 
second type of bone density scan.  The scanner is called a peripheral 
quantitative computed tomography scanner and also uses x-rays to measure 
bone density.  During this visit, you will be asked to participate in 1 set of 3 
scans that measure the shape and structure of your bones. A researcher will 
take 3 scans, one at your ankle, the second at mid-calf and the third at the 
widest cross-section of your calf. During the scans the limb being measured 
will be placed in a positioning device.  Please refer to the pictures we have 
provided. We will conduct the scans while you are seated in a chair or 
wheelchair. This visit will take 45 minutes.  
 
Yearly Follow-up for 2 years 
 You will be asked to return annually for the next two years to repeat the 
medical history, bone density scans, and scans at McMaster. You will be 
called at 6 and 18 months during the two year study to monitor any changes 
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in your health, medication and record if you have had any fractures.  You 
will also be asked to report any broken bones to the study coordinator over 
the two-year period when they occur.   These phone calls will take 
approximately 30 minutes or less. 
 
If you have severe spasticity: During the scans at McMaster, it may be 
difficult for the technologist to position you if you have lower body muscle 
spasms. Only if you have severe lower body muscle spasms, you will be 
asked to take a small dose of Lorazepam (otherwise known as Ativan, dose is 
0.5-1.0 mg below the tongue) to prevent spasms while the scan is taking place. 
If you do not have severe spasticity, you will not need to take Lorazepam. 
Lorazepam is a short acting muscle relaxant that reduces muscle spasms.  
Many people with SCI have taken Lorazepam early after their injury to help 
with sleeping while in hospital. Adverse reactions to Lorazepam, when they 
occur, are usually observed at the beginning of the dose and generally 
decrease in severity or disappear after 2-3 hours.  If you become very drowsy 
with Lorazepam, you may not remember having the pQCT scan. If needed, 
the Lorazepam will be prescribed for you by Dr. Craven on the day of your 
scan. These precautions are taken mainly to reduce the chance of injury in the 
event that a spasm occurs when your leg is placed in the scanning device. You 
do not have to agree to take Lorazepam if you do not wish to do so. 
However, we may decide not to try to scan you if the spasticity limits our 
ability to position you safely. If you have metal implants in both lower legs, 
have broken your shinbones in the past, or have severe leg spasms and are 
allergic to Lorazepam, you will not be able to participate in the study. Also, 
women who may be pregnant or who plan on becoming pregnant cannot 
participate.  If you are a woman, a urine pregnancy test may be performed to 
ensure that it is safe for you to participate. 
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS? 
 
The risks to participants are small. Bone Density scans involve exposure to small 
amounts of radiation. The level of exposure associated with the scans proposed in 
this study is ~30 Sv, which is less than doses received during a computed 
tomography (CT) scan of the chest (30-60Sv) or annually from background 
radiation (2500 Sv). The radiation dose is roughly equal to the dose of radiation 
received over 3 days by every Canadian from natural sources of radiation in the 
environment.  Repeated exposure to radiation has a cumulative risk over time but 




If you are asked to take Lorazepam to reduce your leg spasms during scans in 
Hamilton, there is a risk of side effects.  Amongst a study of 3500 people, the most 
common side effects were sedation (15.9%), dizziness (6.9%), weakness (4.2%) 
and unsteadiness walking (3.4%). Less frequent side effects include disorientation, 
depression, nausea, change in appetite, headache and agitation.  Most side effects, 
if they occur, occur with the first dose of the drug.  Lorazepam will only be given 
to you if necessary.  If you need Lorazepam, it will provided to you at no cost.  
After taking Lorazepam, the study staff will monitor you for an hour or so, to make 
sure you have not had any side effects.  A physician will be available for 
supervision. You should not drive or perform other tasks that require alertness 
immediately after taking Lorazepam. Also, you cannot take Lorazepam if you are 
currently taking the fungal medications ketoconazole (Nizoral or Xolegel) or 
itraconazole (Sporanox).   
 
Women who may be pregnant or who plan on becoming pregnant cannot 
participate in the study as there are risks to exposing a fetus or unborn baby to 
ionizing radiation. 
 
Blood draws can also have side effects and discomforts.  There is a possibility that 
you may experience pain, bruising, bleeding or infection at the site of the needle 
puncture. Blood draws may also temporarily cause headache, nausea and 
lightheadedness. 
 
HOW MANY PEOPLE WILL BE IN THIS STUDY? 
 
80 individuals with SCI will be recruited to participate.  
 
WHAT ARE THE POSSIBLE BENEFITS OF THE STUDY FOR ME AND/OR 
SOCIETY? 
 
We cannot promise any personal benefits to you from your participation in the 
study. If you are interested in learning what your bone density is, we can send your 
bone density scan results to your physician. The study will help us understand bone 
loss in individuals with SCI, and determine risk factors related to bone loss in SCI. 
 
CONFIDENTIALITY AND SECURITY OF DATA 
 
Your data will not be shared with anyone except with your consent or as required 
by law. All personal information will be removed from the data and will be 
replaced with a number. A list linking the number with your name will be kept in a 
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secure place, separate from your file. The data will be securely stored in a locked 
office. For the purposes of ensuring the proper monitoring of the research study, it 
is possible that a member of the Office of Research Ethics at the University of 
Waterloo, Hamilton Health Sciences Research Ethics Board or Toronto Rehab 
Research Ethics Board may consult your research data and medical records. 
However, no records that identify you by name or initials will be allowed to leave 
the hospital. By signing this consent form, you authorize such access. If the results 
of the study are published, your name will not be used and no information that 
discloses your identity will be released or published without your specific consent 
to the disclosure. However, it is important to note that a copy of your signed 
consent form and the data that follows may be included in your health record.  The 
data will be retained indefinitely. 
 
CAN PARTICIPATION IN THE STUDY END EARLY? 
 
If you volunteer to be in this study, you may withdraw at any time and this will in 
no way affect the quality of care you receive. You have the option of removing 
your data from the study. You may also refuse to answer any questions you don’t 
want to answer and still remain in the study. The investigator may withdraw you 
from this research if circumstances arise which make it unsafe for you to continue 
participating and it is in your best interest to withdraw.  You will also be informed 
in a timely manner of any new information that arises during the course of the 
study that may influence your decision to participate.  
 
WILL I BE PAID TO PARTICIPATE IN THIS STUDY? 
 
You will be reimbursed $40 per visit each year ($120 in total over the course of the 
study) to assist with transportation costs to Lyndhurst or Chedoke.  For participants 
traveling to Hamilton from the Toronto area (>50km), transportation is provided 
and you are welcome to have someone accompany you on the trip.  For those 
wishing to use their own transportation for travel between Hamilton and Toronto, 
the stipend will be increased to $140 per visit.   
 
WILL THERE BE ANY COSTS? 
 
Your participation in this research project will not involve any additional costs to 
you or your health care insurer. 
 




If you are injured as a direct result of taking part in this study, all necessary 
medical treatment will be made available to you at no cost. Financial compensation 
for such things as lost wages, disability or discomfort due to this type of injury is 
not routinely available. However, if you sign this consent form it does not mean 
that you waive any legal rights you may have under the law, nor does it mean that 
you are releasing the investigator(s), institution(s) and/or sponsor(s) from their 
legal and professional responsibilities. 
 
IF I HAVE ANY QUESTIONS OR PROBLEMS, WHOM CAN I CALL? 
 
If you have any questions about the research now or later, if you wish to withdraw 
from the study at any time or if you think you have a research-related injury, please 
contact the research coordinator for the study, Lindsie Robertson at (416) 597-
3422 x6301, pager (416) 644-6936 or one of the study investigators below: 
Dr. Craven (416)597-3422 x6122  
Dr. Lora Giangregorio (519) 888-4567 x36357 
Kayla Hummel via e-mail, khummel@uwaterloo.ca  
 
This study has been reviewed and received ethics clearance through the Office of 
Research Ethics (ORE) at the University of Waterloo, the Research Ethics Board at 
the Toronto Rehabilitation Institute and the Research Ethics Board of Hamilton 
Health Sciences/McMaster University Faculty of Health Sciences.  If you have any 
questions regarding your rights as a research participant, you may contact any/all 
of the offices listed below: 
 
Dr. Susan Sykes, Office of Research Ethics (ORE) at the University of Waterloo 
(519) 888-4567 x6005  
 
Dr. Gaetan Tardif - Chair, Toronto Rehab Research Ethics Board (416) 597-3422 x 
3730 
 
Deborah Mazzetti, Office of the Chair of Hamilton Health Sciences/Faculty of 
Health Sciences Research Ethics Board (905) 521- 2100 x42013 
 
IF I DO NOT WANT TO TAKE PART IN THE STUDY 
 
It is important for you to know that you can choose not to participate in the study. 
Your doctor can do tests to look at your bone density even if you do not participate 
in this study.  Choosing not to participate will in no way affect the regular therapy 




If do not want to participate, it is important for us to know if there are significant 
differences between people who choose to participate in our study and people who 
don’t. We ask if you would mind answering 7 brief questions that will be used to 
determine if the group of people who did not participate is different than those who 
did. You can also choose not to answer these questions; it is entirely your decision.  
If you do not want tO be in the study but might want to answer the questions, we 
will review them with you and let you decide. Neither your name nor any 





SIGNATURE OF PARTICICIPANT/LEGALLY-AUTHORIZED 
REPRESENTATIVE 
 
I have read the preceding information thoroughly. I have had the opportunity to ask 
questions, and all of my questions have been answered to my satisfaction. I agree 




Name of Participant  
 
______________________________________ ______________ 
Signature of Participant      Date 
 
If verbal consent is obtained in lieu of a signature, the person obtaining consent 




Consent form administered and explained in person by: 
 
I confirm that I have explained the nature and purpose of the study to the 
participant name above.  I have answered all questions.  I believe the participant 
has the legal capacity to give informed consent to participate in this research study. 
 
_____________________________________ 
Name and title 
 
_____________________________________ ______________ 
Signature        Date 
 
SIGNATURE OF INVESTIGATOR: 
 
















Title of Study: Bone Quality in Individuals with Chronic Spinal Cord Injury 
Primary Investigators:  Dr. Lora Giangregorio and Dr. Catharine B. Craven 
Co-investigators: Dr. Papaioannou, Dr. Popovic, Dr. Thabane, Dr. McCartney and Dr. 
Adachi 
Student Investigator: Kayla Hummel, Dept. of Kinesiology, University of Waterloo 
Sponsor: Canadian Institutes of Health Research 
 
We would like to access your medical chart to verify your medical history. We would 
like to confirm your ASIA classification to see if it has changed, check your surgical and 
medical history and see any bone density scans you have had. By signing below, you are 
giving your consent to allow the coordinator of the study and lead investigators to look at 
your chart. You have the right to choose not to have anyone look at your chart if that is 
your wish.  The information collected from your chart will be used for research purposes 
only. 
 
Consent to give access to chart: 
 
 
________________________    ______________________   ____________ 
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HAS THE CONSENT FORM BEEN SIGNED?      Yes  No   
 
 If yes, proceeed 
 
 
Inclusion Criteria Yes No 
Age ≥18 years of age   
Able to understand instructions in English   
Spinal Cord Impairment of sudden onset for duration of atleast 24 
months (sudden onset <24 hours, C2-T10 ASIA A-D with a stable upper motor neuron, 
neurological deficit of trauma or trauma-like etiology) 
  
Ability to give informed consent   
If NO to any of these criteria, the participant should be excluded 
 
 
Exclusion Criteria Yes No 
Current or prior known condition(s) other than paralysis that are known to 
influence bone metabolism, including; 
  
Oral glucocorticoid use for >3 months   
Known malignancy   
Known liver condition   
Known malabsorption condition   
Other: ________________________   
Weight ≥ 270 lbs   
Contraindications to pQCT testing   
Bilateral metal implants   
Severe spasticity and known allergy to Ativan   
Other: ________________________ 
  
   
Participant is Male   
 
Participant is Female     Please provide the following details and complete following page 
 
 
If Female:   
Participant is Pregnant or planning to become pregnant 
 (Please see following page “Pregnancy Risk and Urine Pregnancy Test”) 
Yes  No  






Y Y Y Y M M D D 
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Pregnancy Risk and Urine Pregnancy Test 
 
Please also refer to Exclusion Criteria 
 
 
Pregnancy Risk  Comments 
Is the participant of child bearing potential? 
(unless postmenopausal for 12 months, does not have 
a uterus and/or ovaries, OR has been surgically 
sterilized for 6 months prior to study) 





Is the participant a sexually active female? 
 Yes      No  
    
 Not Applicable  
 
Is the participant using a reliable method of 
contraception?  
(hormonal methods or intrauterine device 30 days 
prior to study, barrier methods plus spermicidae in use 
atleast 14 days prior to study OR sexual abstinence 
as a lifestyle) 
 Yes      No  
    
 Not Applicable 
 
Risks of ionized radiation exposure during 
pregnancy reiterated? 
 Yes      No  
    
 Not Applicable 
 
 
B-Hcg Test  Comments 
Was the test indicated?  Yes      No  
Was the test performed?  Yes      No  





Y Y Y Y M M D D 
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     Gender:               Male               Female Date of Birth: / /  
                                      Y       Y      Y      Y       M      M        D       D 
Date of injury/onset:  
 
           / /  
                 Y       Y       Y      Y       M      M        D       D  
Time Post Injury:   years 
 Level of Injury  (e.g. T12, C06):            
 N/A 
Cause of injury : ___________________________ 
ASIA Impairment (A-D):  
ASIA Total Motor Score:  
 
ASIA LEMS:  
 
ASIA Sensory Score:  
 
 
Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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    HAVE YOU EVER BROKEN A BONE BEFORE?   YES  NO 
 
IF YES, PLEASE COMPLETE THE FOLLOWING FOR EACH FRACTURE EVENT: 
 
 
1. BONE FRACTURED:         
 
WHEN IT OCCURRED: / /      BEFORE SCI   AFTER SCI                 
            Y     Y     Y    Y       M   M       D    D 
 
HOW DID FRACTURE OCCUR?: 
 TORSION  LOW VELOCITY FALL   ROM 
HYPERFLEXION TRANSFER  OTHER specify:     
 
FRACTURE VERIFIED BY MEDICAL RECORDS:   YES   NO    
 
NOTES:               
 
              
 
 
2. BONE FRACTURED:         
 
WHEN IT OCCURRED: / /      BEFORE SCI   AFTER SCI              
Y                                         Y    Y    Y     Y      M    M      D     D 
 
HOW DID FRACTURE OCCUR?: 
 TORSION  LOW VELOCITY FALL   ROM 
HYPERFLEXION TRANSFER  OTHER specify:     
 
FRACTURE VERIFIED BY MEDICAL RECORDS:   YES   NO    
 
NOTES:               
 




Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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3. BONE FRACTURED:         
 
WHEN IT OCCURRED: / /      BEFORE SCI   AFTER SCI                  
           Y     Y     Y    Y       M    M     D     D 
 
HOW DID FRACTURE OCCUR?: 
 TORSION  LOW VELOCITY FALL   ROM 
HYPERFLEXION TRANSFER  OTHER specify:     
 
 
FRACTURE VERIFIED BY MEDICAL RECORDS:   YES   NO    
 
NOTES:               
 
              
 
 
4. BONE FRACTURED:         
 
WHEN IT OCCURRED: / /      BEFORE SCI   AFTER SCI                  
           Y     Y     Y    Y       M    M      D    D 
 
HOW DID FRACTURE OCCUR?: 
 TORSION  LOW VELOCITY FALL   ROM 
HYPERFLEXION TRANSFER  OTHER specify:     
 
 
FRACTURE VERIFIED BY MEDICAL RECORDS:   YES   NO    
 
NOTES:               
 
              
 
 
Additional sheets as needed 
  
Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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HAVE YOU TAKEN CALCIUM OR VITAMIN D SUPPLEMENTS IN THE PAST? 
 
 
Calcium Supplement    Yes          No          Unknown   If Yes, Mg per day:       
 
Type of Calcium Supplement :    Calcium Carbonate     Calcium Citrate  Unknown        
 
               Other (Specify): ________________  




Vitamin D     Yes            No           Unknown 
 
If Yes, (iu) per day:   Duration (months):  
 
 
Multivitamin     Yes            No           Unknown 
 
Duration (months):  
 
  
Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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HAVE YOU EVER BEEN PRESCRIBED A BISPHOSPHONATE?      
 
Didrocal (Etidronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Fosamax (Alendronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Actonel (Risedronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Aredia (Zolendronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Bonefos/Clasteon/Ostac (Clodronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Skelid (Tiludronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   




  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   




  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
 
  
Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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Bone Quality in Individuals with Chronic Spinal Cord Injury 
 
 
PAST MEDICATION ADVERSELY AFFECTING BONE DENSITY 
 
HAVE YOU EVER BEEN PRESCRIBED ANY OF THE FOLLOWING?  
 
Prednisone 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Tegretol or Dilantin 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Thyroid Medication 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Coumadin (Warfarin) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 




  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   





  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
 
  
Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Testosterone tablets or gel 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Miacalcin 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Other: (Specify):  
 
_______________ 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Other: (Specify):  
 
_______________ 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
 
  
Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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X-RAY - Post SCI of the hip or knee region: 
  
Date:        / /   Anatomic Location :                               
Y                      Y       Y       Y      Y       M      M        D       D      
      
 
If yes, Complete description of fracture location and type in the table below:  





























































Answer only if x-ray was done of the hip/ knee region:  
Subluxation:                 
 
Dislocation:                 
 
Avascular Necrosis:                      
 
Heterotopic 
Ossification:                     
 
Prior Surgery:                 
 
Comments:             
               
 
    
  
Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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CHEMOTHERAPY  YES    NO  YES    NO 
 
RADIOTHERAPY  YES    NO  YES    NO 
 
HYPOGONADISM  YES    NO  YES    NO 
 
THYROID DISEASE  YES    NO  YES    NO 
 
HYPERTHYROIDISM  YES    NO  YES    NO 
 
HYPOTHYROIDISM  YES    NO  YES    NO 
 
INFLAMMATORY BOWEL DISEASE  YES    NO  YES    NO 
 
HYPERPARATHYROIDISM  YES    NO  YES    NO 
 
MYELOMA  YES    NO  YES    NO 
 
VITAMIN D DEFICIENCY  YES    NO  YES    NO 
 
LIVER DISEASE  YES    NO  YES    NO 
 
RENAL FAILURE  YES    NO  YES    NO 
 
CANCER  YES    NO  YES    NO 
 
MUSCULOSKELETAL PROBLEMS  
(I.E. JOINT PROBLEMS, ARTHRITIS, 
CONTRACTURES) 
 YES    NO  YES    NO 
 
CARDIOVASCULAR DISEASE  
(OR FAMILY HISTORY) 
 YES    NO  YES    NO 
 
HIGH BLOOD PRESSURE  YES    NO  YES    NO 
 
HIGH CHOLESTEROL  YES    NO  YES    NO 
 
CHEST PAIN / ANGINA  YES    NO  YES    NO 
 







Y Y Y Y M M D D 
/ / Date of Assessment 
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OTHER DISEASES/CONDITIONS AFFECTING BONE DENSITY 
 
DISEASE/SYSTEM HISTORY OF DISEASE CURRENT DISEASE 
 
OTHER: __________________________ 
 YES    NO  YES    NO 
 
OTHER: __________________________ 
 YES    NO  YES    NO 
 
OTHER: __________________________ 




Y Y Y Y M M D D 
/ / Date of Assessment 
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Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
















Other Neurological (not 





Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 















Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 










Current Health Status 
Visit 
Y Y Y Y M M D D 
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Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 














Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 














Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 














Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 










Current Health Status 
Visit 
Y Y Y Y M M D D 
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Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 















Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 














Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 














Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 










Current Health Status 
Visit 
Y Y Y Y M M D D 
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Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
















Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
















Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
















Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 









Additional pages as required 
  
Current Health Status 
Visit 
Y Y Y Y M M D D 
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  Dates of Use 









Oral   
IV   
IM   
SC   
Rectal   
Topical   
Other:  
Frequency 
QD   
BID 
TID 
QID   
HS 
PRN   
Other:  
 
Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
 
Stop Date : 
/ /  












Oral   
IV   
IM   
SC   
Rectal   
Topical   
Other:  
Frequency 
QD   
BID 
TID 
QID   
HS 
PRN   
Other:  
 
Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
 
Stop Date : 
/ /  












Oral   
IV   
IM   
SC   
Rectal   
Topical   
Other:  
Frequency 
QD   
BID 
TID 
QID   
HS 
PRN   
Other:  
 
Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
 
Stop Date : 
/ /  




Additional pages as required 
  
Concurrent Medication 
Y Y Y Y M M D D 
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HEIGHT:  .  cm          
 
 Not Available 
WEIGHT:  .  kg         
 
 Not Available 




ARE YOU PRE-MENOPAUSAL, PERI-MENOPAUSAL OR POST-MENOPAUSAL? 
If they are unsure, skip to next question.  
 PRE  PERI   POST 
 
If they are pre- or peri-menopausal, or unsure ask: HOW LONG AGO WAS YOUR LAST PERIOD?  (do not 
count periods that occurred while taking hormones) 
 
 LESS THAN ONE YEAR  1-3 YRS  
 3-10 YRS  MORE THAN 10 YEARS 
 
If they are post-menopausal, ask: WAS YOUR LAST PERIOD GREATER THAN 10 YEARS AGO? 
 NO  YES 
 
If NO, ask: WAS YOUR LAST PERIOD LESS THAN 5 YEARS AGO? 
 NO  YES 
 
HAVE YOU EVER HAD A HYSTERECTOMY OR HAD BOTH YOUR OVARIES REMOVED OR RADIATED?   








Y Y Y Y M M D D 
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DO YOU CURRENTLY SMOKE?   YES     NO #/DAY      
 
HAVE YOU EVER BEEN A SMOKER?   YES   NO   
      
IF YES TO ABOVE, PLEASE WRITE DOWN WHEN THEY STARTED AND STOPPED SMOKING 
(YEAR). ALSO PLEASE INDICATE HOW MANY CIGARETTES PER DAY, ON AVERAGE. IF AMOUNT 
SMOKED VARIED OVER TIME, PLEASE DESCRIBE. 
 
START   STOP   #/DAY  
              Y Y  Y Y              Y  Y  Y  Y   
 
 
DO YOU CURRENTLY DRINK ALCOHOL?   YES  NO   #/DAY   n/a 
BEER (bottles per week)  
WINE (glasses per week)  
LIQUOR (oz. per week)  
 
DO YOU HAVE A HISTORY OF ALCOHOL CONSUMPTION? 
 YES  NO   #YEARS    n/a 
BEER (bottles per week)  
WINE (glasses per week)  




1. HAVE YOU EVER FELT YOU SHOULD CUT DOWN ON YOUR DRINKING? 
   YES  NO 
2. HAVE PEOPLE ANNOYED YOU BY CRITICISING YOUR DRINKING? 
   YES  NO 
3. HAVE YOUR EVERY FELT BAD OR GUILTY ABOUT YOUR DRINKING? 
   YES  NO 
4. HAVE YOUR EVER HAD A DRINK FIRST THING IN THE MORNING TO STEADY 
YOUR NERVES OR GET RID OF A HANGOVER (EYE-OPENER)? 
  YES  NO 
Health Demographics 
Visit 
Y Y Y Y M M D D 
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PLEASE INQUIRE IF THE PARTICIPANT HAS EXPERIENCED ANY OF THESE 
COMPLICATIONS IN THE PAST 3 MONTHS (CHECK ALL THAT APPLY): 
 AUTONOMIC DYSREFLXIA  BLADDER INFECTION  
 PAIN  DEEP VEIN THROMBOSIS  
 PRESSURE SORE  CONSTIPATION 
 SPASTICITY  HETEROTOPIC OSSIFICATION 
 HEMORRHOIDS  BLADDER/KIDNEY STONES  
 INGROWN TOE NAIL   DRUG ADDICTION  
 GI BLEED   NEUROLOGIC DETERIORATION  
 LOW BLOOD PRESSURE   GYNECOLOGICAL PROBLEMS 
 SURGERY  













Y Y Y Y M M D D 
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1.  (a) Have you had any hospital admissions in the past six months which required an overnight stay? 
(not in emergency)   (1) Yes  (2) No (if no go to question 2) 
 
(b)  For what reason were you admitted to hospital? (check all that apply) 
  (1) Heart Disease    
  (2) Pressure Sores    
  (3) Blood Clot    
  (4) Cancer Treatment specify:      
 (5) Bladder/Kidney Infection 
 (6) Fracture specify:      
 (7) Surgery specify:       
 (8) Medical or Diagnostic Test specify:      
 
2. (a) Have you broken one or more bones in the past six months? 
 (1) Yes -go to (b)  (2) No (If no, thank participant, questionnaire complete) 
 
(b) How many times have you fractured a bone in the last six months?   
 
Complete the following pages (one fracture incident form for each fracture) 
Fracture Ascertainment Questionnaire 
Visit 
Y Y Y Y M M D D 
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Bone Quality in Individuals with Chronic Spinal Cord Injury 
 
 
Complete the following pages (one fracture incident form for each fracture) 
1. What was the date of the fracture?    
  / /  
Y   Y  Y   Y   M   M   D   D  
  
 Don’t know 
2. Which bone was broken? 
 1 Back  (specify if available)____________________    
 2 Hip         1 Left    2 Right 
 3 Ribs/Sternum       1 Left    2 Right 
 4 Forearm/ Wrist       1 Left    2 Right 
 5 Pelvis        
 6 Shoulder (upper arm)      1 Left    2 Right 
 7 Elbow        1 Left    2 Right 
 8 Hand        1 Left    2 Right 
 9 Finger(s)        1 Left    2 Right 
 10 Knee        1 Left    2 Right 
 11 Ankle        1 Left    2 Right 
 12 Foot        1 Left    2 Right 
 13 Upper Leg          1 Left    2 Right 
 14 Lower Leg        1 Left    2 Right 
 15 Toe(s)        1 Left    2 Right 
 16 Other (specify) _________________________     1 Left    2 Right    3 N/A 
  
Fracture Ascertainment Questionnaire 
Visit 
Y Y Y Y M M D D 
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3. Based on the Interviewers discretion and participant history, was this an incident or fragility 
fracture? 
 1 Incident 
 2 Fragility 
4. How did the fracture happen? 
 1  Fell out of bed or off a chair (from sitting position) 
 2  Fell climbing a chair or ladder 
 3  Fell on stairs 
 4  Motor vehicle accident 
 5  Sporting injury 
 6  Slipped or tripped inside the home 
 7  Slipped or tripped outside the home 
 8  Heavy object fell or struck body causing the fracture 
 9 Catching foot or ankle in doorway 
 10 Bone(s) broke with no fall or injury 
 11 Car Transfer  
 12 Other Transfer specify:     
 13 Unknown 
 14 Other (specify) ____________________ 
 
5. What time of day did the fracture occur?   
 1  Day (8am to 4pm)     2  Evening (4pm to midnight)    3 Night (midnight to 8am) 
6. Were X-rays of the fracture taken?   1 Yes    2 No   3 Don’t know 
If Yes or Don’t know, obtain consent from participant to acquire the X-ray from health record 
MAIL CONSENT FORM TO PARTICIPANT  
Fracture Ascertainment Questionnaire 
Visit 
Y Y Y Y M M D D 
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Was the fracture treated by a physician?   1 Yes  2  No (go to question 9) 
 
7. Where was the fracture first noticed?  (Check all the apply)  
 Hospital  Physician’s office  
                                    (go to question 10) (go to question 11)    
      
 Home Other 
(go to question 12) (go to question 12) 
 
 
8. Where was the decision made on how to manage your fracture?  (Check all the apply) 
 Hospital  Physician’s office  
                                    (go to question 10) (go to question 11)    
      
 Home Other 
(go to question 12) (go to question 12) 
 
  
Fracture Ascertainment Questionnaire 
Visit 
Y Y Y Y M M D D 
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10. IN HOSPITAL   -    
Date of Admission : 
/ /  
Y  Y   Y  Y     M M     D D  
 
 Don’t know 
 
 1 Emergency Clinic       2 Fracture Clinic      3 In-Patient →    Length of stay  days 
Hospital Name  _________________________  Don’t know 
Treating Doctor  ________________________  Don’t know 
Treatment received   1 Surgery  2 Cast  3 Other (specify) ________________ 
   ↓ 
      1 Internal and or external fixation (pins, nails, screws) 
      2 Joint replacement 
Where did you go when you left the hospital? 
 1 Home 
 2 Rehabilitation centre           What was the name? ____________ Length of stay:  days 
 3 Convalescent home  
 4 Other (specify) ___________________ 
11. IN PHYSICIAN’S OFFICE Physician’s name _______________ 
Date of first visit:      Total number of visits:   
/ /  
Y  Y   Y  Y     M M     D D  
 
Treatment received:    1 Cast  2 Other (specify) __________________ 
 
  
Fracture Ascertainment Questionnaire 
Visit 
Y Y Y Y M M D D 
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12.  As a consequence of your fracture, were you treated with Physiotherapy?   1 Yes   2 No 
                   ↓ 
        # of visits # of weeks 
    in hospital       
    in public rehabilitation centre    
    in private convalescent centre    
    community health centre     
    private clinic      
    at home from a private clinic    
    in senior’s home      
 
13. As a consequence of your fracture were you visited by an occupational therapist?  
 1 Yes   2 No 
If yes, hours per week  # of weeks  
If subject has not yet returned home from inpatient stay, go to question 17 
14. As a consequence of your fracture, were you visited at home by a nurse? 
  1 Yes   2 No 
If yes, hours per week  # of weeks  
15. As a consequence of your fracture, did you receive help from a homemaker? (meals on wheels, 
housekeeping, personal hygiene)  
 1 Yes   2 No 
If yes, hours per week  # of weeks  
Fracture Ascertainment Questionnaire 
Visit 
Y Y Y Y M M D D 
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16. As a consequence of your fracture, did you receive help from an attendant?  
 1 Yes   2 No 
If yes, hours per week  # of weeks  
17. As a consequence of your fracture, did you receive help from a family member or friend? 
 1 Yes   2 No↓ 
How many days did you receive help?    days 
Did this person have a paying job?   1  Yes  2  No 
     ↓ 
  How many days off work did this person  
  take as a result of your fracture?                ________ days 
 
18. Since the fracture, have you temporarily given up any of your usual activities? 
 1 Yes   2 No  If yes, specify:      
 
19. Since the fracture, have you permanently given up any of your usual activities? 
 1 Yes   2 No  If yes, specify:      
20. Since the fracture do you go out:   1 Less often   2 The same   3 More often 
21. Have you been told that your fracture is osteoporosis related?  
 1 Yes   2 No   3 Don’t know 
 
For each fracture incidence, complete the following X-ray Form
Fracture Ascertainment Questionnaire 
Visit 
Y Y Y Y M M D D 
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  For each fracture, complete an X-ray Form 
 
 
1. Was the consent for medical records abstraction received? 
 
 1 Yes   2 No   
 
X-ray Source:  1 Hospital     2 Physician’s Office     3 Clinic 
 
Any Fracture?  1 Yes   2 No   3 Unknown 
 
 
If yes, complete description of fracture location and type in table below: 
 
Fracture site identified by X-ray 
 
Fracture Location  Side Fracture Type 
 Hip 
 Mid shaft femur 
 Distal Femur 
 Proximal tibia 
 Midshaft tibia 
 Distal tibia 
 Other  
________________ 
 
 Right   Left 
 Right   Left 
 Right   Left 
 Right   Left 
 Right   Left 
 Right   Left 




 Stress/Undisplaced Fracture 
 Compound 







Y Y Y Y M M D D 
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       210  
4. 
Yogurt 
250 mL        305  
         TOTAL  
 
 
Average Dietary Calcium (mg/day) = Total of mg Calcium Per Month / 30 = .
 mg/day 
 
Please update participant’s contact information and obtain an alternate contact, in the 
event that the participant becomes unreachable in future.  
  
Food Frequency Questionnaire Participant ID 
Phone Call 
Y Y Y Y M M D D 
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If severe and frequent lower extremity spasticity, complete 
following page prior to administration of Ativan and pQCT scan 
SPASM FREQUENCY 
 
0 = No Spasm 
1 = Spasm induced only by stimulation 
2 = Infrequent spontaneous spasms occurring less than once per hour 
3 = Spontaneous spasms occurring more than once per hour 
4 = Spontaneous spasms occurring more than ten times per hour 
 
Right  Left 
   
0 1 2  3  4 Arm 0  1  2  3  4 
   
0 1 2  3  4 Leg 0 1 2  3    4 
   
0 1 2  3  4 Trunk 0 1 2  3    4 




2 = Moderate 
3 = Strong 
 
Right  Left 
   
1 2  3   Arm  1 2  3   
   
1 2  3   Leg 1 2  3 
   
1 2  3   Trunk 1 2  3   
   
Spasm Frequency & Severity Scale 
Visit 
Y Y Y Y M M D D 
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If severe and frequent lower extremity spasticity, complete this form.  
 
 Yes No 
Is Ativan indicated?   
   
Any contraindication to Ativan administration?   
Is the participant currently taking ketoconazole or itraconazole?   
Does the participant have a history of respiratory insufficiency?   
Does the participant us BT-PAP or C-PAP at night?   
Does the participant have a history of allergy or adverse reaction to Ativan?   
Are there any concomitant medications that may interact with Ativan (Viagra, 
Narcotics, SSRIs) 
  
If contraindications, subject should NOT be given Ativan prior to 
pQCT 
 





Ativan Safety Form 
Visit 
Y Y Y Y M M D D 
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Feedback for Research Participants 
 
Title of Study: Bone quality in individuals with chronic spinal cord injury 
Primary Investigators: Dr. Lora Giangregorio and Dr. Cathy Craven 
 
Contact Information for Primary Investigators: 
 
Dr. Craven Phone: (416) 597-3422 x6122    Email: craven.cathy@torontorehab.on.ca 
 
Dr. Giangregorio Phone: (519) 888 4567 x36357    Email: lmgiangr@healthy.uwaterloo.ca 
 
Research Coordinator: Lindsie Robertson  
Phone:(416) 597-3422 x6301 Email: robertson.lindsie@torontorehab.on.ca 
 
Co-investigators:  Dr.Milos Popovic, Dr. Neil McCartney, Dr. Alexandra Papaioannou,             
Dr. Lehana Thabane, Dr. Rick Adachi 
 
Student Investigator:  Kayla Hummel khummel@uwaterloo.ca 
 
Funding Source:  Canadian Institutes of Health Research 
 
Recently you took part in a research study where your bone health was evaluated. We 
would like to thank you for taking the time to participate in the study. The purpose of the 
study was to better understand how bone changes occur after spinal cord injury.  
 
The main findings of the study are as follows: 
 
(include findings here in point form) 
 
Please remember that any data pertaining to yourself as an individual participant will be kept confidential.  
Once all the data are collected and analyzed for this project, I plan on sharing this information with the 
research community through seminars, conferences, presentations, and journal articles 
 
This study has been reviewed and received ethics clearance through the Office of Research 
Ethics at the University of Waterloo, the Research Ethics Board at the Toronto Rehabilitation 
Institute and the Research Ethics Board of Hamilton Health Sciences/McMaster University 
Faculty of Health Sciences. If you have any questions regarding your rights as a research 
participant, you may contact: Dr. Gaetan Tardif, Toronto Rehabilitation Institute of Research 
Ethics Board at (416) 597-3422 x 3730 or Dr. Susan Sykes of University of Waterloo Research 
Ethics Board at 519-888-4567, x 36005, ssykes@uwaterloo.ca or Deborah Mazzetti of Office of 
the Chair of Hamilton Health Sciences/Faculty of Health Sciences Research Ethics Board at 




Dr. Catharine B. Craven 
 
Co-investigators: 
Dr. A. Papaioannou 
Dr. M. Popovic 
Dr. L. Thabane 
Dr. N. McCartney 





























Figure 1. Vitamin D metabolism and its role in bone tissue, kidneys and intestine 
Figure 2. Participant recruitment flow diagram  
Figure 4. Linear regression of distal femur aBMD and serum 25(OH)D 
Figure 5. Linear regression of proximal tibia aBMD and serum 25(OH)D 
Figure 6. Linear regression of 4% tibia trabecular vBMD and serum 25(OH)D  
Figure 7. Linear regression of 66% tibia cortical vBMD and serum 25(OH)D 
Figure 8. Linear regression of 66% tibia cortical thickness and serum 25(OH)D 
Figure 11. Linear regression of serum ionized calcium and intact PTH  
Figure 13. Linear regression of 4% tibia trabecular vBMD and serum intact PTH 
Figure 14. Linear regression of 66% tibia cortical vBMD and intact serum PTH 
Figure 15. Linear regression of distal femur aBMD with serum intact PTH  
Figure 16. Linear regression of proximal tibia aBMD with serum intact PTH 





























Figure 4. Linear regression of distal femur aBMD (g/cm
2
) and serum 25(OH)D (nmol/L).  
 
 
Figure 5. Linear regression of proximal tibia aBMD (g/cm
2

























































y = -0.00087x + 0.736 
R
2
 = 0.025 
y = -0.00091x + 0.587 
R
2









Figure 6. Linear regression of 4% tibia trabecular vBMD (mg/cm
3




Figure 7. Linear regression of 66% tibia cortical vBMD (mg/cm
3





























































y = -0.0255x + 1082.7  
R
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 = 0.00 
y = -0.004x + 144.82 
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Serum Intact PTH (pmol/L)
y = -0.0016x + 3.408 
R
2
 = 0.00 
y = -0.0035x + 1.245 
R
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Figure 13. Linear regression of 4% tibia trabecular vBMD (mg/cm
3




Figure 14. Linear regression of 66% tibia cortical vBMD (mg/cm
3




























































Serum Intact PTH (pmol/L)
y = -6.793x + 175.801 
R
2
 = 0.086 
y = -4.504x + 1107.173 
R
2








Figure 15. Linear regression of distal femur aBMD (g/cm
2




Figure 16. Linear regression of proximal tibia aBMD (g/cm
2





























































Serum Intact PTH (pmol/L)
y = 0.0006x + -.676 
R
2
 = 0.00 
y = -0.0045x + 0.534 
R
2

































r = -0.011 
p = 0.962 
